
PHYSIOLOGICAL REVIEWS
Vol. 76, No. 4, October 1996
Printed in U.S.A.

# Mechanism of Signaling by Growth Hormone Receptor

LAWRENCE S. ARGETSINGER AND CHRISTIN CARTER-SU

Department of Physiology, University of Michigan Medical School, Ann Arbor, Michigan

---

I. Introduction                                                                                       1089
II. Growth Hormone Receptor                                                                           1090
    A. Growth hormone binding and receptor dimerization                                              1090
    B. Cytokine/hematopoietin receptor superfamily                                                   1091
III. Growth Hormone-Dependent Intracellular Signaling                                                1093
    A. Activation of JAK2 tyrosine kinase                                                            1093
    B. Growth hormone-dependent tyrosyl phosphorylation of growth hormone receptor and JAK2          1095
    C. Activation of the mitogen-activated protein kinase signaling pathway by growth hormone        1095
    D. Utilization of insulin receptor substrates 1 and 2 and phosphatidylinositol 3′-kinase         1096
       by growth hormone
    E. Role of protein kinase C in signaling by growth hormone                                      1097
    F. Regulation of intracellular calcium and nitric oxide synthase by growth hormone              1098
    G. Activation of Stat family proteins by growth hormone                                         1099
IV. Conclusions                                                                                       1100

---

Argetsinger, Lawrence S., and Christin Carter-Su. Mechanism of Signaling by Growth Hormone Receptor. Physiol. Rev. 76: 1089–1107, 1996.—Growth hormone (GH) has long been known to stimulate linear growth and regulate metabolism. The cellular mechanism by which GH elicits these effects has only recently begun to be understood. This review provides an overview of a current model of GH signaling. Briefly, binding of GH to GH receptor induces receptor dimerization and activation of the tyrosine kinase JAK2. Tyrosyl phosphorylation of GH receptor and JAK2 recruits and activates signaling molecules such as Stat transcription factors, SHC, and insulin receptor substrates 1 and 2 that lead to the release of second messengers such as diacylglycerol, calcium, and nitric oxide and the activation of enzymes such as mitogen-activated protein kinase, protein kinase C, phospholipase A₂, and phosphatidylinositol 3′-kinase. These pathways regulate cellular function including gene transcription, metabolite transport, and enzymatic activity that result in the ability of GH to control body growth and metabolism.

---

## I. INTRODUCTION

and patients with acquired immune deficiency syndrome (116, 171).

To realize fully the therapeutic potential of GH, a mechanistic appreciation of GH action at the cellular and molecular level is essential. The cloning of GH (124, 175) and GH receptor (GHR) (122) has provided critical tools for the study of GH signaling. With these tools in hand, our understanding of GH signaling has expanded rapidly in the past several years. Considerable information has been obtained concerning the initial event in GH signal transduction, the binding of GH to its receptor. Determination of the structure of GH bound to the extracellular domain of GHR (designated GHBP for GH binding protein) (47) has provided critical information for the design of GH agonists and antagonists and led to general acceptance of the model of a single GH bound to a GHR-GHR dimer as the initial event in GH signaling (226). Homology recognized among a number of receptors, including GHR, led to the recognition of a new receptor superfamily, the

0031-9333/96 $15.00 Copyright © 1996 the American Physiological Society

cytokine/hematopoietin receptor superfamily (12). Within this family of receptors, the finding that ligand binding to the receptors for GH (7), erythropoietin (230), and interleukin-3 (183) activates JAK2 tyrosine kinase identified a putative signaling mechanism for these receptors and led to the realization among researchers studying what were once thought to be diverse receptor systems that there may be signaling pathways shared by these receptors. As a consequence of these findings, a number of signaling molecules have recently been identified that interact with the GHR/JAK2 complex or are activated in response to the GH. Signaling pathways utilizing these molecules as well as the physiological role played by these pathways are beginning to be identified. This review provides an overview of this current understanding of GH signal transduction. While our knowledge of these pathways is still rudimentary, the studies discussed in this review have greatly expanded our understanding of how GH acts and interacts with other growth factors and cytokines to elicit its effects on growth and metabolism.

### II. Growth Hormone Receptor

Growth hormone receptor was initially cloned from rabbit and human liver cDNA libraries (122) and subsequently was cloned from mouse (189), rat (125), cow (93), chicken (21), pig (32), and sheep (1) cDNA libraries. Among species, the amino acid sequence identity is ~70% (reviewed in Refs. 112, 187). The importance of the cloned GHR in regulation of growth is substantiated by the detection of deletions and point mutations in the gene encoding GHR in individuals with Laron dwarfism (4, 5, 75) and in chickens with sex-linked dwarfism (50, 103). Metabolic functions have also been ascribed to GHR. When expressed in cells, the cloned GHR elicits GH-dependent insulin production in rat insulinoma (RIN-5A) cells (18, 16, 131), protein and lipid synthesis in Chinese hamster ovary (CHO) cells (52, 132), and proliferation in FDC-P1 cells and Ba/F3 cells (36, 219).

Physically, GHR is characterized by an \( M_r \) of ~130,000 (7, 122, 195, 217). Growth hormone receptor contains a single transmembrane domain (Fig. 1). Five potential N-linked glycosylation sites are conserved in the extracellular domain of the GHR in species sequenced to date. Several of these are glycosylated (reviewed in Ref. 90). The extracellular domain contains six cysteines that are linked by disulfide bonds and one free cysteine (64). Growth hormone receptor purified from rabbit liver is covalently linked to ubiquitin (\( M_r \sim 9,000 \)) on a mole percent basis of 20–50% (122). Ubiquitin is known to target proteins for degradation (97); therefore, the short half-life (~45 min) reported for GHR in isolated rat adipocytes (80) may be a consequence of this modification.

#### A. Growth Hormone Binding and Receptor Dimerization

Studies performed with the extracellular domain of GHR (GHBP) using crystallography, size exclusion chromatography, calorimetry, and fluorescence quenching experiments suggest that one GH binds two GHR (39, 47). When \({}^{125}\)I-labeled GH is covalently cross-linked to full-length or truncated GHR in intact cells, the detection of complexes with \( M_r \) appropriate for GH(GHR)\(_2\) complexes suggests that GH is also bound to GHR dimers in vivo (L. Rui, L. S. Argetsinger, D. Virgo, and C. Carter-Su, unpublished data). Analysis of the structure of the GH-bound GHBP dimer reveals that the two binding sites on human GH (hGH) are on opposite sides of the hGH. Surprisingly, in GHBP the two GH binding sites are largely composed of the same residues and have similar overall shape and structure. The amino acid residues that form sites 1 and 2 in GHBP are situated in six clusters between residues 43 and 218. Site 1 consists of 33-amino acid side chains that define a contact region of 1,300 Å (47). Within site 1, a functional epitope of 11 amino acids appears to be involved in GH binding as assessed by a loss in binding affinity when the individual amino acids are mutated to alanine (33). For site 2 of GHBP, 31 amino acids define a contact region of 900 Å, of which 8 account for 85% of the binding energy (40). The cysteine pairs in GHBP are embedded in the ligand-binding domain and the WSXWS-like motif, conserved in all receptors of the cytokine/hematopoietin receptor superfamily (see sect. II.B), lies at the base of the ligand binding domain and the dimerization interface. Growth hormone binding to the GHR-GHR complex is hypothesized to be sequential (39). The initial step is high-affinity binding of GH to site 1 in GHR. Contacts at site 2 and an ~500 Å contact region between the two extracellular domains of GHR stabilize the binding of the second GHR (reviewed in Ref. 226).

Growth hormone receptor dimerization appears to be required for proliferation. A monoclonal antibody (MAb5) that binds to the interface between GHR-GHR dimers and therefore would be expected to prevent formation of dimeric GHR-GHR complexes is an antagonist of GH-dependent cellular proliferation (39). Furthermore, contact at site 2 in the context of a GHR-GHR dimer appears to be necessary for proliferation. An hGH variant (G120R) defective in site 2 binding but with normal binding affinity for GHR only very weakly promotes proliferation (63). In contrast, although an hGH variant (K172A/F176A) defective in site 1 binding has a 1,000-fold right shift in the 50% effective concentration for cell proliferation, it also has a 560-fold decrease in binding affinity, suggesting that for the GH site 1 mutant, the decrease in cellular proliferation results mainly from a reduced ability to bind GHR.

The stoichiometry of a single GH binding two GHR and the fact that the two binding sites on GHR are largely composed of the same residues suggests that GH at high

October 1996                                                                                               SIGNALING BY GROWTH HORMONE                                                                                              1091

![Figure](#fig1)

FIG. 1. Growth hormone receptor (GHR). Potential N-linked glycosylation sites (N) and extracellular cysteines (C) with 3 pairs linked by disulfide bonds are noted. Transmembrane domain is shown in black. Ten tyrosines (Y) present in cytoplasmic region of rat GHR are noted. Position of WSXWS-like motif is indicated by striped box. Intracellular box 1 (proline-rich domain) and box 2 are identified. Regions of GHR required for various functions are indicated. MAP kinase, mitogen-activated protein kinase; IRS, insulin receptor substrate. [Modified from Smit and Carter-Su (187).]

GH receptor

concentrations should be a self-antagonist. Indeed, in cell-based proliferation assays, this is the case. Consistent with the inability of G120R to bind at site 2 and the consequent failure to transduce a signal, G120R is a better antagonist than GH by a factor of 100 (62). The antagonistic effect of G120R is also evident in vivo; a transgenic strain of mice that expresses the bovine equivalent of G120R produces dwarf mice (30). Thus endogenous GH can be antagonized with GH containing a single mutation in binding site 2 of GH. This and the finding that the functional binding epitope on GHBP (and presumably GH) is much smaller than the contact region suggests that it may be possible to design small molecular antagonists of GH for therapeutic use (33).

B. Cytokine/Hematopoietin Receptor Superfamily

Growth hormone receptor is a member of the cytokine/hematopoietin receptor superfamily (12). In addition to GHR, this superfamily (see Fig. 2) includes receptors for ciliary neurotrophic factor (CNTF) (45), erythropoietin (Epo) (41), granulocyte colony stimulating factor (G-CSF) (66), granulocyte-macrophage colony stimulating factor (GM-CSF) (70), interleukin (IL)-2 (92), IL-3 (114), IL-4 (134), IL-5 (201), IL-6 (12, 234), IL-7 (79), IL-9 (156), IL-11 (100), IL-12 (31), prolactin (PRL) (12, 19), and thrombopoietin (213). The superfamily also includes receptor subunits that interact with more than one cytokine receptor (see Fig. 2), including gp130 (98), the β-subunit of leukemia inhibitory factor (LIF) receptor (71),

the IL-3 receptor common β-chain (βc, previously termed KH97 or AIC2β) (114), and the γ-chain of the IL-2 receptor (202). Gp130 is a subunit of the receptors for IL-6 (98), IL-11 (57), oncostatin M (OSM) (69), CNTF, and LIF (106). The β-subunit of the LIF receptor is present in the receptors for LIF, CNTF, and OSM (71). The IL-3 receptor common β-chain is present in the receptors for IL-3, IL-5, and GM-CSF (107, 81). The γ-chain of the IL-2 receptor is a component of the receptors for IL-2, IL-4, IL-7 (202), IL-9 (167), IL-15 (74), and potentially IL-13 (240). The more distantly related class II receptors in the cytokine/hematopoietin receptor superfamily (13, 101) include the IL-10 receptor (101), both the α-subunit (209) and β-subunit (141) of the interferon (IFN)-α/β receptor, and both the α-subunit (2) and β-subunit (96, 190) of the IFN-γ receptor.

The ligands for many members of this large superfamily were identified based on their ability to mediate communication between cells in immune and hematopoietic systems. In contrast, the receptors for GH, PRL, and CNTF were first identified in the endocrine and neural systems. Initially, most of these ligands were thought to elicit specific effects in a relatively restricted group of cells. However, more recent work has shown that most of them elicit a wide range of biological effects on a broad range of tissues and cells (reviewed in Refs. 113, 146). Growth hormone is typical of this with responses reported in many cell types including cells in the immune system (115) and endocrine system (187). The recognition that these receptors have a common ancestry, and in several

LAWRENCE S. ARGETSINGER AND CHRISTIN CARTER-SU

G-CSF

GH PRL EPO
IL-3 GM-CSF IL-5
CNTF LIF OSM IL-6 IL-11
EPOR G-CSF R
GHR PRLR
IL-3 Ra
GM-CSF Ra
IL-5 Ra
Aic-2/β chain
Aic-2/β chain
Aic-2/β chain
CNTFR
LIF-Ra
LIF-Rb
gp 130
gp 130
gp 130
IL-6 R
IL-11 R
gp 130
IL-3 receptor common β chain

Thrombopoietin
IL-12
IL-2 IL-4 IL-7 IL-9 IL-15 IL-10 IFN-γ IFN-α
mpl
IL-12 R
IL-2 Ra
IL-2 Ry
IL-2 Rβ
IL-2 Ry
IL-2 Rβ
IL-2 Ry
IL-2 Rβ
IL-2 Ry
IL-2 Rβ
IL-2 Ry
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rβ
IL-2 Rpairs of positionally conserved cysteine residues and a single tryptophan residue. In the class II receptors, only one pair of cysteines is conserved. The second fibronectin domain is defined by the consensus sequence WSXWS (tryptophan, serine, any amino acid, tryptophan, serine) usually located proximal to the membrane. Mutational studies in Epo receptor, IL-2 receptor β-chain, and PRL receptor have shown that the WSXWS motif is essential for ligand binding and subsequent signal transduction (129, 150, 163, 221). Indicative of the importance of this motif, in GH-resistant sex-linked dwarf chickens, the final serine in the GHR WSXWS-like motif (YXXFS in mammalian GHR) is mutated to isoleucine. This mutant GHR has reduced affinity for GH (50). Alanine-scanning mutagenesis of the WSXWS-like motif of GHR suggests that the first aromatic residue and the last serine residue are critical for GH binding and consequent signal transduction (11). Because the WSXWS-like motif in GHR does not make direct contact with GH (47), the WSXWS motif is likely to serve a structural role critical for ligand binding.

In the intracellular region, two motifs have been recognized in GHR and other members of the cytokine/hematopoietin receptor superfamily (42, 136, 143). A proline-rich motif, referred to as box 1, is situated in close proximity to the membrane. Box 1 is eight amino acids in length with a consensus sequence of ΨXXXAlPXP (Ψ, hydrophobic; X, any amino acid; Al, aliphatic; and P, proline). In mammalian GHR, the sequence is ILPPVPVP. The other cytoplasmic motif (box 2) begins with a cluster of hydrophobic amino acids interspersed with acidic amino acids and ends with one or two positively charged amino acids (136). In GHR, box 2 begins ~30 amino acids COOH-terminal to box 1 and spans ~15 amino acids (42). Mutation or deletion of box 1 and/or box 2 in GHR, G-CSF receptor, β-chain of IL-2 receptor, PRL receptor, Epo receptor, β-chain of LIF receptor, or gp130 results in defective ligand-mediated cellular growth in IL-3-dependent cell lines expressing the appropriate receptor. This suggests that these regions play critical roles in receptor-mediated signal transduction (10, 42, 65, 76, 95, 136, 219).

signal transduction (7). Initially, GH-dependent activation of the Janus kinases in 3T3-F442A fibroblasts or IM-9 cells was thought to be limited to JAK2 (7, 180); however, with the use of a higher affinity JAK1 antibody, low-level tyrosyl phosphorylation of JAK1 has been detected in response to GH in 3T3-F442A fibroblasts (188) and in COS cells cotransfected with murine GHR and JAK1 cDNAs (W.-H. Huo and C. Carter-Su, unpublished data). In a transformed T cell line, GH also stimulates tyrosyl phosphorylation of JAK3, although to a substantially smaller extent than IL-2, a potent activator of JAK3 (110). Whether GH activates tyk2 is unclear. Growth hormone-dependent phosphorylation of tyk2 was not detected in IM-9 cells (7); however, low-level activation could have been missed. Thus, in addition to the rapid and robust activation of JAK2 in response to GH, JAK1 and JAK3 may also be activated to a lesser extent and thereby mediate some of the effects of GH.

Signaling through the JAK kinases is not limited to GHR. Many, if not all, members of the cytokine/hematopoietin receptor superfamily activate members of the JAK kinase family (see Table 1). Thus not only do some of the receptors in this superfamily share receptor subunits, but a common group of kinases is also activated. Together, these findings provide a mechanistic basis for the redundancy in signaling observed with the cytokines (reviewed in Ref. 113). However, specificity in signaling is also evident. The individual cytokines activate different combinations of the JAK kinases (see Table 1). Even when the same JAK kinases are activated, the level and duration of activation of the JAK kinases vary substantially in response to stimulation by different cytokines. In 3T3-F442A fibroblasts, GH stimulates tyrosyl phosphorylation of JAK2 more than 15 times as effectively as LIF or IFN-γ. The duration of JAK2 tyrosyl phosphorylation is prolonged following IFN-γ stimulation when compared with either GH or LIF stimulation. In contrast, these ligands stimulate tyrosyl phosphorylation of JAK1 to a similar extent (8, 188). These quantitative differences in level and duration of activation of the JAK kinases may be sufficient to produce qualitative phenotypic differences in signaling. Consistent with this, the duration and strength of the GH signal (and presumably JAK activation) appear to be critical for at least some GH signaling. Pulsatile variations in serum GH characteristic of male rats (peaks of 200–300 ng/ml decreasing to undetectable levels) are necessary for transcription of the male-specific cytochrome P-450-2C11 and P-450–3A10 genes while relatively constant lower levels of GH (10–20 ng/ml) characteristic of female rats stimulate P-450–2C12 and suppress P-450–2A2, -2C11, -2C13, -3A2, and -3A10 gene transcription (133, 196, 222). Specificity in signaling also arises from the tissue-specific expression of each particular cytokine receptor and consequent targeting of responses to specific cell types. In addition, signaling molecules that specifically interact

III. GROWTH HORMONE-DEPENDENT INTRACELLULAR SIGNALING

A. Activation of JAK2 Tyrosine Kinase

In response to GH, the tyrosine kinase JAK2 becomes rapidly activated, and JAK2 is detected in a complex with GHR (7, 212). JAK2 is a member of the Janus family of cytoplasmic tyrosine kinases that currently includes JAK1, JAK2, JAK3, and tyk2 (55, 91, 183, 228, 231). The rapidity of onset and GH sensitivity (combined with its detection in every cell type tested) led to the hypothesis that JAK2 activation may be the initiating step in GHR
TABLE 1. Association of Janus kinases with cytokine/hematopoietin receptors

| Receptor                          | JAK1   | JAK2   | JAK3   | Tyk2   | Reference No. |
|-----------------------------------|--------|--------|--------|--------|---------------|
| **Class I receptors**             |        |        |        |        |               |
| GHR subfamily                     |        |        |        |        |               |
| GHR                               | +      | +++    | +      |        | 7, 110; W.-H. Huo and C. Carter-Su, unpublished data |
| PRLR                              |        | +++    |        |        | 26, 166       |
| EpoR                              |        | +++    |        |        | 230           |
| G-CSFR                            | +++    | +++    |        |        | 140, 176      |
| Receptors that interact with IL-3R common β-chain |        |        |        |        |               |
| IL-3R                             |        | +++    |        |        | 183           |
| IL-5R                             |        | +++    |        |        | 170           |
| GM-CSFR                           |        | +++    |        |        | 151           |
| Receptors that interact with gp130 |        |        |        |        |               |
| CNTFR*                            | +++    | +++    |        | +      | 193           |
| LIFR*                             | +++    | +++    |        |        | 193, 236      |
| OSMR*                             | +++    | +++    |        | +      | 193, 236      |
| IL-6R*                            | +++    | +++    |        | +++    | 193, 236      |
| IL-11R                            |        | +++    |        | +      | 14, 236       |
| IL-12R                            |        | +++    |        | +++    | 9             |
| Thrombopoietin receptor            |        | +++    |        |        | 49            |
| Receptors that interact with IL-2R common γ-chain |        |        |        |        |               |
| IL-2R                             | +      | +      | +++    |        | 110, 203, 231 |
| IL-4R                             | +      |        | +++    |        | 231           |
| IL-7R                             | +      |        | +++    |        | 167, 238      |
| IL-9R                             | +++    |        | +++    |        | 167           |
| IL-13R                            |        |        |        |        |               |
| IL-15R                            |        |        |        |        |               |
| **Class II receptors**            |        |        |        |        |               |
| IFN-αR                            | +++    |        | +      | +++    | 110, 135, 193 |
| IFN-γR                            | +++    | +++    |        | +      | 110, 135, 220 |
| IL-10R                            | +++    |        | +++    |        | 54a           |

For a particular ligand, Janus kinase(s) showing substantial activity or autophosphorylation are denoted +++, and those for which only minimal ligand-dependent tyrosyl phosphorylation is detected are denoted +. * Specific Janus kinases activated vary between cell lines (193). GHR, growth hormone receptor; PRLR, prolactin receptor; EpoR, erythropoietin receptor; G-CSFR, granulocyte colony stimulating factor; IL, interleukin; IFN, interferon; GM-CSFR, granulocyte-macrophage colony stimulating factor; CNTFR, ciliary neurotrophic factor receptor; LIFR, leukemia inhibitory factor receptor; OSMR, oncostatin M receptor.

kine receptors that interact with JAK1, JAK3, and tyk2 should provide insight into the molecular basis for the specificity of the various cytokine receptors for individual JAK kinases. The ability to study these interactions in a large number of receptors is likely to reveal some fundamental elements of intermolecular signaling.

The central role that JAK2 plays in GH signaling is clearly evident from studies using mutated GHRs that fail to bind or activate JAK2. These mutants fail to elicit GH-dependent tyrosyl phosphorylation of SHC proteins, the mitogen-activated protein (MAP) kinases designated extracellular signal regulated kinase (ERK) 1 and ERK 2, insulin receptor substrate (IRS) 1, IRS-2, and induction of spi 2.1 gene promoter constructs when expressed in CHO cells, GH-dependent insulin synthesis in RIN-5AH cells, and mitogenesis when expressed in FDC-P1 cells and Ba/F3 cells (8, 16, 36, 83, 131, 210, 219). Growth hormone-dependent calcium transport is the only action of GH presently reported where there is evidence for regulation by a pathway independent of JAK2 (17). Conceivably, some GH-dependent pathways may only require that JAK2 be activated. Consistent with this hypothesis, a rat GHR/JAK2 chimera directly linking the kinase domain of JAK2 to the external and transmembrane domains of GHR supports GH-dependent transcriptional activation of c-fos promoter constructs (59).

or Y627 in pig GHR is required for GH-dependent transcription of spi 2.1/CAT constructs (89) and that Y487, Y534, Y566, or Y627 is required for GH-promoted tyrosyl phosphorylation of Stat5 (233). Y333 and/or Y338 in rat GHR appears to be required for GH-stimulated lipid and protein synthesis (123) and maximal activation of Stats 1, 3, and 5 (188) (see Fig. 1). Thus multiple tyrosines in GHR appear to play a role in different actions of GHR.

### C. Activation of the Mitogen-Activated Protein Kinase Signaling Pathway by Growth Hormone

One of the initial findings leading to the hypothesis that GH activates a tyrosine kinase was the observation that GH stimulates the tyrosyl phosphorylation of a large number of cellular proteins, both cytoplasmic and nuclear (23, 85, 181). This suggests that JAK2 phosphorylates proteins in addition to JAK2 and GHR and/or that JAK2 activation initiates signaling pathways that involve activation of other tyrosine kinases or inactivation of tyrosine phosphatases. Two such proteins that are rapidly phosphorylated and activated in response to GH are the MAP kinases ERK 1 and ERK 2 (6, 25, 229). The MAP kinases are serine/threonine kinases that require phosphorylation on both a tyrosine and threonine for activation (35). In addition to GH-dependent activation, MAP kinases are activated by a number of receptor and nonreceptor tyrosine kinases. They are believed to be important in the regulation of growth and differentiation (35).

One pathway by which the membrane receptor tyrosine kinases activate MAP kinases involves SHC, Grb2, son-of-sevenless (Sos), ras, raf, and MAP/ERK kinase (MEK) (reviewed in Ref. 38) (see Fig. 3). In 3T3-F442A and CHO cells expressing rat GHR, GH promotes rapid tyrosyl phosphorylation of the 46-, 52-, and 66-kDa splice variants of SHC (210). Experiments using the SH2 domain of the SHC proteins fused to glutathione S-transferase suggest that GH stimulates association of SHC proteins with JAK2-GHR complexes via the SH2 domain of SHC proteins. Studies using truncated and mutated GHR suggest that SHC proteins may bind to phosphorylated residues in both GHR and JAK2 (210). Direct association between SHC and JAK2 is also indicated for Epo receptor-JAK2 signaling (94). If SHC associates with JAK2, presumably JAK2 also phosphorylates SHC. Consistent with this, GHR mutants that fail to bind and activate JAK2 also fail to phosphorylate SHC and activate ERK 1 and ERK 2 (210, 212). The next step in the pathway leading to MAP kinase activation, Grb2 association with tyrosyl phosphorylated SHC, has also been detected (210). Although the remaining molecules in this signaling cascade (Sos, ras, raf, and MEK) have not yet been shown to be activated by GH, it seems likely that JAK2 activation and the recruitment of SHC and Grb2 are early events in GH-dependent activation of ERK 1 and ERK 2.

1096 LAWRENCE S. ARGETSINGER AND CHRISTIN CARTER-SU Volume 76

Glucose

GH  
GHR  

JAK2  

IRS  

PI3K  

RAS  

SOS  

Grb2  

SHC  

p90<sup>RSK</sup>  

RAF  

MEK  

MAPK  

PLA₂  

Stats  

Stat1 Stat3 SRF SRF TCF  

SIE SRE c-fos  

PC-PLC  

DAG  

PKC  

GLE-2 P450-3A10  

Stat5  

GLE-1 Spi 2.1  

Ca²⁺  

FIG. 3. GHR signaling pathways. Possible signaling pathways initiated by binding of GH to its receptor are shown. Shaded molecules and solid arrows indicate molecules and pathways regulated by GH. Dotted arrows and unshaded molecules indicate molecules or pathways utilized by other growth factors but not yet shown to be involved in GH-dependent signal transduction, or pathways with only limited data to support their existence. GLE, interferon-γ-activated sequence (GAS)-like response element; PLA₂, phospholipase A₂; PLC, phospholipase C; PKC, protein kinase C; DAG, 1,2-diacylglycerol; SIE, Sis-induced element; SRE, serum response element; SRF, serum response factor; spi 2.1, serine protease inhibitor 2.1; PI3K, phosphatidylinositol 3′-kinase; TCF, ternary complex factor. [Modified from Smit and Carter-Su (187).]

Mitogen-activated protein kinases have been reported to phosphorylate and activate a variety of proteins, including phospholipase A₂, cytoskeletal proteins, protein kinases (e.g., c-Raf-1, the S6 kinases designated p70<sup>rsk</sup> and p90<sup>rsk</sup>), and transcription factors (e.g., c-Jun and the ternary complex factor, p62<sup>TCF</sup>/Elk1) (reviewed in Ref. 44). Of these substrates, GH has been shown to activate phospholipase A₂ in rat hepatocytes (206) and the S6 kinase, p90<sup>rsk</sup>, in 3T3-F442A fibroblasts (6) (see Fig. 3). Increased phospholipase A₂ activity resulting in increased levels of arachidonic acid and subsequent formation of arachidonic acid metabolites by the P-450 enzyme system has been implicated in the Ca²⁺-dependent GH induction of the P-450-2C12 gene (206). p90<sup>rsk</sup> phosphorylates cellular proteins, including serum response factor, a transcription factor that binds to the serum response element (SRE) of the c-fos promoter (159). The SRE confers GH-dependent transcriptional regulation of a c-fos reporter construct.

(128). Another substrate of MAP kinases that binds the SRE, the ternary complex factor p62<sup>TCF</sup>/ELK1, is also likely to be involved in GH action (see Fig. 3). Although p62<sup>TCF</sup>/ELK1 is constitutively bound to the SRE, transcriptional activation of p62<sup>TCF</sup>/ELK1 requires phosphorylation of a cluster of serine and threonine residues by the MAP kinase ERK 2 (72, 99). Consistent with MAP kinases playing a role in the GH induction of c-fos expression, regions of GHR implicated in MAP kinase activation have also been implicated in c-fos gene expression (78).

D. Utilization of Insulin Receptor Substrates 1 and 2 and Phosphatidylinositol 3′-Kinase by Growth Hormone

In cells and tissues that have been deprived of GH, GH is known to have rapid insulin-like effects including

October 1996                                                                                               SIGNALING BY GROWTH HORMONE                                                                                              1097

![Diagram](#fig4)

FIG. 4. GHR signaling via insulin receptor substrate-1 (IRS-1). Growth hormone-dependent tyrosyl phosphorylation of IRS-1 and recruitment of phosphatidylinositol 3'-kinase (PI3K) by IRS-1 is shown. Shaded molecules and solid arrows indicate molecules and pathways regulated by GH. Unshaded molecules and dotted arrows indicate signaling proteins known to bind IRS-1 via SH2 domain-mediated interactions (Nck, Grb-2, SHPTP2), proteins with enzymatic activities that are stimulated by action of PI3K, or signaling pathways utilized in cells treated with insulin. These have not yet been shown to be involved in GH signal transduction.

increased amino acid transport, glucose transport, and lipogenesis (43). This suggests that GH and insulin may activate some common signaling pathways. Consistent with this, GH has been shown to stimulate the tyrosyl phosphorylation of IRS-1 in primary cultures of rat adipocytes, in 3T3-F442A fibroblasts, and in CHO cells expressing rat GHR (8, 157, 192) and a related protein, IRS-2, in 3T3-F442A fibroblasts and in CHO cells expressing rat GHR (L. S. Argetsinger, M. G. Myers, Jr., N. Billestrup, G. Norstedt, M. F. White, and C. Carter-Su, unpublished data). Insulin-like growth factor I (IGF-I; 137), IL-4 (216, 215), IFN-γ, LIF (8), IFN-α (208), IL-9 (235), and IL-13 (225) have also been shown to stimulate tyrosyl phosphorylation of IRS-1 and/or IRS-2.

Specific tyrosines in GHR are not required for IRS-1 or IRS-2 phosphorylation (8; Argetsinger et al., unpublished data), and neither GHR nor JAK2 contains the NPXY consensus sequence required for the interaction of IRS-1 with the receptors for insulin, IGF-I, and IL-4 (111, 144). Therefore, the nature of the GH-stimulated interaction with IRS-1 is likely to differ from the interaction with the receptors for insulin, IGF-I, and IL-4. Studies using truncated and mutated GHRs expressed in CHO cells suggest that 1) tyrosyl phosphorylation of IRS-1 and IRS-2 is dependent on JAK2 activation, 2) the role of GHR in GH-dependent tyrosyl phosphorylation of IRS-1 and IRS-2 may be to activate JAK2, and 3) interaction of the GHR-JAK2 complex with IRS-1 and IRS-2 occurs through activated JAK2 either directly or via an intermediary protein.

Tyrosyl phosphorylation of IRS-1 and IRS-2 in response to insulin provides binding sites for specific proteins containing SH2 domains, including the 85-kDa regulatory subunit of phosphatidylinositol (PI) 3'-kinase (197–199), Grb2 (138, 184), the tyrosine phosphatase SHPTP2 (117, 120), and Nck (121) (see Fig. 4). Similarly, GH promotes the binding of the 85-kDa regulatory subunit of PI 3'-kinase to IRS-1 and IRS-2 (8, 157; Argetsinger et al., unpublished data). Phosphatidylinositol 3'-kinase has been implicated in insulin-stimulated glucose transport, DNA synthesis, and the activation of p70<sup>rsk</sup>, an enzyme implicated in cell cycle progression (28). Consistent with a role for PI 3'-kinase in activating the insulin-like metabolic effects of GH, the PI 3'-kinase inhibitor wortmannin blocks the ability of GH to stimulate lipid synthesis (and presumably glucose transport, the rate-limiting step in lipid synthesis) (158). Furthermore, GH-dependent phosphorylation of IRS-1 and IRS-2, lipid synthesis, and glucose transport all require the NH<sub>2</sub>-terminal, but not the COOH-terminal, half of the cytoplasmic domain of GHR (78, 132).

Growth hormone is likely to promote the association of proteins with IRS-1 and IRS-2, in addition to PI 3'-kinase. However, not all signaling molecules that bind IRS-1 and IRS-2 following insulin stimulation necessarily bind in response to GH. Differences in the specificities of JAK2 and insulin receptor could result in phosphorylation of unique subsets of tyrosyl residues, thereby changing the complement of binding sites available and hence the signaling molecules bound. The potential for interaction with a large number of pathways dictates that the influence of IRS-1 and IRS-2 on GH signaling may be substantial.

E. Role of Protein Kinase C in Signaling by Growth Hormone

The ability of GH to stimulate lipogenesis (186), induce c-fos expression (87, 185, 207), stimulate binding of nuclear protein to C/EBP oligonucleotide (34), and increase intracellular Ca<sup>2+</sup> concentration ([Ca<sup>2+</sup>]<sub>i</sub>) (67) is reduced by the addition of inhibitors of protein kinase C (PKC) and/or chronic treatment of cells with phorbol 12-myristate 13-acetate to deplete PKC. This suggests that

these actions of GH may require activation of PKC or be modulated by PKC. Whether PKC is involved in the activation of MAP kinases and p90<sup>rsk</sup> by GH remains controversial (6, 25, 229).

Protein kinase C is a family of serine/threonine kinases consisting of at least 12 isoforms that phosphorylate and activate multiple proteins. They are considered important regulators of cellular growth, differentiation, and metabolism (46, 104). The isoforms differ substantially in structure, regulation, tissue and developmental expression, and substrate specificity. For most of the isoforms of PKC, activation and translocation from the cytosol to the cellular membrane is mediated by the second messengers Ca<sup>2+</sup> and/or 1,2-diacylglycerol (DAG). Activation of the α-, β-, and γ-isoforms requires Ca<sup>2+</sup>; however, the δ-, ε-, ζ-, ν- and θ-isoforms are Ca<sup>2+</sup> independent. The requirement for DAG may not be absolute, since other components of glycerolipid metabolism have recently been shown to activate some PKC isoforms. Therefore, the pathways utilized to activate PKC have important implications for PKC signaling. For instance, the inositol 1,4,5-trisphosphate (IP<sub>3</sub>) pathway that generates both Ca<sup>2+</sup> and DAG could activate PKC isoforms distinct from the isoforms activated following phospholipase C- or phospholipase D-mediated hydrolysis of phosphatidylcholine with generation of just DAG (reviewed in Refs. 46, 104).

Growth hormone has been shown to elicit rapid transient increases in DAG in multiple cell types (48, 109, 161, 207, 162). The signaling pathways utilized to stimulate DAG production may not be the same in all cell types. In Ob1771 and 3T3-F442A preadipocytes, a relatively small increase in DAG is accompanied by a relatively small increase in phosphocholine (27, 142) (see Fig. 3). In Ob1771 cells, these increases are blocked by pertussis toxin (27). This suggests that in these cells, GH stimulates DAG production from phosphatidylcholine breakdown involving a phospholipase C coupled to GHR via a pertussis toxin-sensitive G protein. In contrast, in kidney proximal tubule membranes, the GH-dependent increase in DAG is accompanied by a rapid transient increase in the level of IP<sub>3</sub> (161), suggesting that in the kidney proximal tubule, GH stimulates DAG production from phosphatidylinositol. In rat adipocytes, GH-induced DAG production is blocked by a tyrosine kinase inhibitor, genistein (162), which also inhibits JAK2 (G. S. Campbell and C. Carter-Su, unpublished data). This finding is consistent with GH-dependent PKC activation lying downstream of JAK2 in these cells. It is also consistent with GH-dependent PKC activation requiring a genistein-sensitive tyrosine kinase other than JAK2.

Phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate, byproducts of PI 3′-kinase, have recently been shown to activate the Ca<sup>2+</sup>-independent PKC isoforms δ, ε, and ν (205). The findings that GH induces translocation of the ε-isoform of PKC from the cytoplasm to the plasma membrane in 3T3-F442A fibroblasts (142) and that the PI 3′-kinase inhibitor wortmannin inhibits GH-dependent DAG formation in rat adipocytes (162) raise the possibility that in some cell types GH activation of PKC may involve IRS-1, IRS-2, and PI 3′-kinase.

Consistent with JAK kinase linked receptors activating PKC, pathways involving PKC have been identified for other cytokine receptors, including the receptors for IL-2, -3, -4, and -6, Epo, IFN-γ, GM-CSF, and PRL (102, 53, 77, 149, 153, 155, 169). As with activation of PKC following GH treatment, activation of PKC by these cytokines proceeds via numerous, and perhaps cell-type specific, signaling pathways. Interleukin-3 and IL-4 appear to stimulate DAG production by means of phosphatidylcholine breakdown involving a phospholipase C (102, 153). In contrast, Epo has been shown to activate phospholipase C-γ1 and stimulate the formation of IP<sub>3</sub> (155). As suggested for GH (142), the ε-isoform of PKC has been implicated in the actions of the IFN-γ and high-affinity IL-2 receptors, with IL-2 receptors also involving the ζ-isoform (77, 169). In contrast, the PKC isoforms α and β have been implicated in the actions of IL-3 (152), and the β- and ζ-isoforms have been implicated in the actions of the medium-affinity IL-2 receptor (77). Whether all cytokines that activate the JAK kinases utilize the same PKC pathways in a particular cell type or whether the individual receptors or specific JAK kinases activated provide specificity in response awaits further investigation.

### F. Regulation of Intracellular Calcium and Nitric Oxide Synthase by Growth Hormone

Growth hormone has been reported to cause a relatively modest, sustained increase in intracellular free calcium concentrations in IM-9 lymphocytes (105) and isolated rat adipocytes (67, 172, 174), but not in Ob1771 or 3T3-F442A preadipocytes (27, 142). Growth hormone-induced oscillations in intracellular Ca<sup>2+</sup> levels of varying frequency and amplitude have also been reported in RIN-5AH cells and CHO cells expressing rat GHR (17). The increase in [Ca<sup>2+</sup>]<sub>i</sub> is dependent on the presence of extracellular Ca<sup>2+</sup> and is blocked by both verapamil and nimodipine (17, 67), suggesting that GH activates L-type calcium channels. The GH-induced increase in [Ca<sup>2+</sup>]<sub>i</sub> in rat adipocytes is mimicked by DAG and blocked by the PKC inhibitor calphostin C and a specific inhibitor of phospholipase C (67), leading to the hypothesis that GH activates L-type calcium channels by a mechanism that involves phospholipid hydrolysis and activation of PKC (see Fig. 3). Indicative of the importance of Ca<sup>2+</sup> in GH signaling, the Ca<sup>2+</sup> channel blocker verapamil inhibits GH-induced expression of a *spi* 2.1 promoter/CAT construct (17) and liberation of arachidonic acid and expression of P450–2C12 (206). Verapamil also inhibits the onset

of a state in rat adipocytes where the cells are refractory to the transient insulin-like effects of GH on glucose metabolism (68).

Preliminary studies suggest that the Ca²⁺-dependent enzyme involved in maintaining the refractory state in rat adipocytes may be an isoform of nitric oxide synthase. Nitric oxide synthase catalyzes the conversion of L-arginine to L-citrulline and the release of nitric oxide (20). The hypothesized involvement of nitric oxide synthase is based on the findings that 1) the refractory state induced by GH is reversed by a competitive inhibitor of nitric oxide synthase; 2) a nitric oxide generator rendered cells refractory to GH; and 3) GH was found to stimulate nitric oxide synthase activity only in refractory cells (173).

G. Activation of Stat Family Proteins by Growth Hormone

Growth hormone is known to elicit a number of physiological responses by regulating the transcription of the genes for a variety of proteins, including GLUT1 glucose transporter, IGF-I, low-density lipoprotein receptor, transcription factors (e.g., c-Fos, c-Jun, c-Myc), metabolic enzymes (e.g., hormone-sensitive lipase, spi 2.1, some isoforms of cytochrome P-450), (15, 119, 126, 130, 133, 145, 164, 200, 222, 237). Indirect evidence suggests that some of the signaling pathways already discussed (e.g., MAP kinase, PKC, Ca²⁺, phospholipase A₂) contribute to the regulation of these genes. Another important pathway by which GH and most of the other cytokines that activate the JAK kinases regulate gene transcription involves the signal transducers and activators of transcription (Stat) proteins (see Fig. 3). Stat proteins are latent cytoplasmic transcription factors. Upon tyrosyl phosphorylation, cytoplasmic Stat proteins complex with other Stat and/or non-Stat proteins, presumably by interactions involving the SH2 and SH3 domains of the Stat proteins, translocate to the nucleus, bind to DNA, and activate transcription of target genes.

Growth hormone has been shown to induce tyrosyl phosphorylation of Stat 1, Stat 3, and Stat 5 in 3T3-F442A fibroblasts (24, 127, 88, 188), in liver from hypophysectomized rats treated with GH (85, 86, 223), and in CHO cells expressing recombinant GHR (188). Stat 1/p91 was originally identified in IFN signaling (62), Stat 3/acute phase response factor in IL-6 and LIF signaling (3, 224, 239), and Stat 5/mammary gland factor in PRL signaling (214).

Consistent with a role as transcription factors, these Stat proteins are present in GH-induced DNA binding complexes for several genes. In nuclear extracts from Ba/F3 cells transfected with GHR, Stat 1 has been identified in GH-induced complexes that bind to the IFN-γ response region (GRR) of the fgr1 gene and to the Sis-inducible element (SIE) in the c-fos promoter (219). Stat 1 has similarly been identified in GH-induced SIE binding complexes prepared from 3T3-F442A cells (127) and liver from hypophysectomized rats (85). Stat 3 is also present in GH-induced SIE binding complexes prepared from 3T3-F442A cells (24) and liver from hypophysectomized rats (86), both in complexes that contain Stat 1 and complexes that do not contain Stat 1. On the basis of the observation that Stat 1 forms homodimers through SH2-phosphotyrosine interactions (177), the existence of GH-induced complexes that contain Stat 1 and Stat 3 as well as complexes that contain only the individual Stats suggests that GH promotes the formation of Stat 1 homodimers, Stat 3 homodimers, and Stat 1/Stat 3 heterodimers, all of which bind to the SIE of the c-fos gene. Stat 4 may be a minor component in SIE binding complexes in liver (86). Growth hormone-dependent Stat 5 binding to the IFN-γ-activated sequence (GAS)-like response element (GLE-1) in the spi 2.1 gene has been detected using CHO cells expressing GHR and in liver from hypophysectomized rats (232). Stat 5 has also been shown to be present in IM-9 cells in a GH-inducible complex that binds to the lactogenic hormone responsive region (179) and in liver cells in a GAS-like DNA binding site in the promoter of the gene encoding P-450-3A10/6β-hydroxylase, a cytochrome P-450 that catalyzes the 6β-hydroxylation of lithocholic acid and is expressed in the liver of male but not female hamsters (196). Mimicking the male GH secretion pattern in females induces expression of the gene to male levels. The DNA binding site to which this Stat 5 containing complex binds has been shown to confer GH induction of P-450-3A10/6β-promoter activity. Consistent with Stat 5 being activated in a sexually dimorphic manner, the Stat 5-containing complex is more abundant in male than in female hamster livers, is absent in hypophysectomized female livers, and is restored when hypophysectomized females are injected with GH in a manner that masculinizes female hamsters in terms of P-450-3A10/6β-hydroxylase expression (196). Thus Stat 1, Stat 3, Stat 5, and perhaps Stat 4 appear to be involved in GH signaling (see Fig. 3).

Interestingly, GH was not observed to activate Stat 1 or Stat 3 in IM-9 cells (54, 180). This is not due to the absence of Stat 1, since IFN-γ was effective in activating Stat 1 in those cells. Thus activation of specific Stats by GH may be cell-type dependent. This could restrict the GH regulation of some genes to only a certain subset of cell types.

Understanding the mechanism by which Stat proteins become phosphorylated, their DNA binding activity stimulated, and their ability to regulate gene transcription is critical for understanding gene regulation by the Stat proteins. Analysis of GH signaling in a JAK2-deficient cell line and in several cell lines expressing truncated and mutated GHRs indicates that GH-dependent Stat activation requires JAK2 activation (188, 219). This is consistent with

similar findings that JAK kinase activation is required for Stat activation by other ligands that bind to cytokine family receptors (135, 220). Because Stat proteins are phosphorylated in response to ligand binding, JAK activation could be required to phosphorylate the Stat proteins. Additionally or alternatively, JAK activation could result in the phosphorylation of specific tyrosine residues within the JAK kinase itself or a receptor subunit, thereby providing a high-affinity binding site for the SH2 domain in the Stat proteins. In support of the former hypothesis, coexpression of JAK1 or JAK2 with Stat 3 in human kidney fibroblast 293 cells activates Stat 3 (154). Similarly, either JAK1 or JAK2 is able to activate endogenous Stat 1 when the kinases are expressed in COS cells (182). In support of the latter hypothesis, phosphorylation of specific tyrosines within gp130, LIF, and IFN-γ receptor subunits appears to be required for ligand activation of Stat 1 and Stat 3 (84, 194). Similarly, phosphorylation and DNA binding activity of Stat 5 in response to GH requires regions of the GHR not required for JAK2 activation, suggesting that Stat 5 interacts with GHR. Tyrosines 333 and/or 338 (rat GHR), 534, 566 and 627 (pig GHR) have been implicated for a maximal response (188, 233). For activation of Stat 1 and Stat 3 by GH, no specific phosphorylated tyrosines in GHR appear to be required, although they may be required for a maximal response (188, 218). The lack of a requirement for specific phosphorylated tyrosines is consistent with the absence in GHR of the Stat 3 (YXXQ) or Stat 1 association motifs found in gp130/LIF and IFN-γ receptor subunits, respectively (84, 194). In contrast, JAK2 contains two Stat 3 association motifs and a Stat 1-like association motif. Thus, for GH which is an extremely effective activator of JAK2 (7, 8), JAK2 may both provide a high-affinity binding site for Stat 1 and Stat 3 and phosphorylate Stats 1 and 3. In contrast, for LIF which results in a level of JAK2 phosphorylation more than an order of magnitude less than that observed for GH in the same cell (8), seven copies of the Stat 3 YXXQ motif present in the LIF receptor enhance the efficiency of Stat 3 tyrosyl phosphorylation by JAK2. Alternatively, GH may utilize an intermediary protein in Stat activation or a region of the GHR other than a phosphorylated tyrosine.

The Stat proteins appear to be components of a very short signaling pathway between the cytokine receptors and target genes, involving tyrosyl phosphorylation of the protein, binding to other Stat proteins, and movement to the nucleus. However, recent studies suggest that tyrosyl phosphorylation of Stat proteins may in some cases not be sufficient for DNA binding (51) and/or for subsequent activation of transcription of at least some target genes (82, 227). Both Stat 1 and Stat 3 show ligand-dependent serine, as well as tyrosine, phosphorylation. For IFN-γ and IFN-α, serine, as well as tyrosine, phosphorylation appears to be required for maximal activation of gene transcription (227). The finding that in GH-treated cells

the majority of tyrosyl phosphorylated Stat 3 migrates in sodium dodecyl sulfate polyacrylamide gels as if it were phosphorylated on serine residues as well as tyrosine residues (24, 188) suggests that serine phosphorylation of Stat proteins may also be important for GH-mediated gene transcription via Stat proteins. Thus multiple signaling pathways may converge on Stat proteins and contribute to transcriptional activation by GH.

Growth hormone regulation of gene transcription may also require interactions between transcription factors bound to multiple response elements in the promoter of specific genes. In the c-fos promoter, both the SIE which binds Stat proteins and the SRE which is not known to bind Stat proteins have been implicated in the regulation of c-fos gene expression by GH (24, 127, 128). These findings are consistent with experiments with transgenic animals that suggest that the SIE, SRE, and cAMP response element are all required for normal expression of c-fos (160). The case for multiple pathways originating with GHR and converging prior to DNA transcription is also supported by the finding that GH regulation of the spi 2.1 promoter requires a more restricted region of the GHR than phosphorylation of Stat 5. Thus, although Stat 5 is believed to be necessary for expression of spi 2.1 by GH, other signaling molecules may also be required (89, 188, 232, 233) (see Fig. 1). A requirement for additional covalent modification of the Stats or interactions with multiple promoter elements stimulated by different signaling pathways would allow for very tight, ligand-specific regulation of the transcription of these genes.

IV. CONCLUSIONS

Understanding of the signaling mechanisms triggered by the binding of GH to its receptor has rapidly advanced in the past several years. The structure of GH bound to a GHBP dimer has been determined. Growth hormone stimulation has been shown to activate JAK2, SHC, Grb 2, MAP kinase, IRS-1, IRS-2, Stat proteins, phospholipase A₂, and PKC. The second messengers DAG, Ca²⁺, and nitric oxide have been detected following GH stimulation. Transcription of the genes encoding IGF-I, some of the P-450 isozymes, spi 2.1, c-fos, and insulin has been demonstrated in response to GH. A model of GH signaling incorporating these findings begins with GH binding GHR and inducing formation of GHR-GHR dimers. The GH(GHR)₂ complex has increased affinity for JAK2 and activates of JAK2 tyrosine kinase activity. The activation of JAK2 appears to be necessary for much of GH signaling. Tyrosyl phosphorylation of JAK2 and GHR, presumably by JAK2, provides binding sites for the SH2 domains of specific signaling molecules, thus activating specific signaling pathways. Interactions via SH2 domains are involved in the activation of the MAP kinase cascade (via an interaction with SHC) and Stat proteins. Mitogen-activated protein kinase is known

to phosphorylate and thereby activate some transcription factors. Stat proteins are likely to play a role in GH-dependent induction of several genes including the c-fos gene, a gene thought to be important for cellular differentiation. Not all interactions with the GHR-JAK2 complex are mediated by SH2 domains; neither IRS-1 nor IRS-2 contains SH2 domains. Activation of JAK2, however, appears to be necessary, and IRS-1 and IRS-2 are tyrosyl phosphorylated in response to GH. This creates binding sites in IRS-1 and IRS-2 for the SH2 domains of specific proteins such as PI 3'-kinase. Growth hormone-dependent elevation in intracellular Ca²⁺, insulin synthesis, and transcription of the genes for spi 2.1 and insulin appear to require interaction with the COOH-terminal half of GHR. Thus, even though activation of JAK2 appears to be necessary for most GH signal transduction, multiple regions of GHR participate in the regulation of metabolism and growth by GH. Because the JAK kinases are stimulated by multiple cytokines, the ability to compare the regulation of signaling pathways utilized by GH with those utilized by other members of the cytokine/hematopoietin receptor superfamily should allow for great insight into the regulation of cellular signaling by all cytokines including GH and provide a greater mechanistic understanding of how GH acts and interacts with other growth factors to elicit its effects on growth and metabolism.

We thank Drs. Nils Billestrup, Stuart Frank, H. Maurice Goodman, Paul Kelly, John J. Kopchick, Peter E. Lobie, Gunnar Norstedt, Peter Rotwein, Michael J. Waters, and James Wells for providing preprints of their current work.

This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants RO1-DK-34171 and RO1-DK-48283.

---

**REFERENCES**

1. ADAMS, T. E., L. BAKER, R. J. FIDDES, AND M. R. BRANDON. The sheep growth hormone receptor: molecular cloning and ontogeny of mRNA expression in the liver. *Mol. Cell. Endocrinol.* 73: 135–145, 1990.
2. AGUET, M., Z. DEMBIC, AND G. MERLIN. Molecular cloning and expression of the human interferon-gamma receptor. *Cell* 55: 273–280, 1988.
3. AKIRA, S., Y. NISHIO, M. INOUE, X.-J. W. S. WANG, T. MATSUSAKA, K. YOSHIDA, T. SUDO, M. NARUTO, AND T. KISHIMOTO. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. *Cell* 77: 63–71, 1994.
4. AMSELEM, S., P. DUQUESNOY, O. ATTREE, G. NOVELLI, S. BOUSNNINA, M. C. POSTEL-VINAY, AND M. GOOSSENS. Laron dwarfism and mutations of the growth hormone-receptor gene. *N. Engl. J. Med.* 321: 989–995, 1989.
5. AMSELEM, S., M. L. SOBRIER, P. DUQUESNOY, R. RAPPAPORT, M. C. POSTEL-VINAY, M. GOURMELEN, B. DALLAPICCOLA, AND M. GOOSSENS. Recurrent nonsense mutations in the growth hormone receptor from patients with Laron dwarfism. *J. Clin. Invest.* 87: 1098–1102, 1991.
6. ANDERSON, N. G. Growth hormone activates mitogen-activated protein kinase and promotes intracellular tyrosine phosphorylation in 3T3-F442A preadipocytes. *Biochem. J.* 284: 649–652, 1992.
7. ARGETSINGER, L. S., G. S. CAMPBELL, X. YANG, B. A. WITT-HUHN, O. SILVENNOINEN, J. N. IHLE, AND C. CARTER-SU. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. *Cell* 74: 237–244, 1993.
8. ARGETSINGER, L. S., G. W. HSU, M. G. MYERS, JR., N. BILLESTRUP, G. NORSTEDT, M. F. WHITE, AND C. CARTER-SU. Growth hormone, interferon-gamma, and leukemia inhibitory factor promoted tyrosyl phosphorylation of insulin receptor substrate-1. *J. Biol. Chem.* 270: 14685–14692, 1995.
9. BACON, C. M., D. W. McVICAR, J. R. ORTALDO, R. C. REES, J. J. O'SHEA, AND J. A. JOHNSTON. Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. *J. Exp. Med.* 181: 399–404, 1995.
10. BAUMANN, H., A. J. SYMES, M. R. COMEAU, K. K. MORELLA, Y. F. D. WANG, S. F. ZIEGLER, J. S. FINK, AND D. P. GEARING. Multiple regions within the cytoplasmic domains of the leukemia inhibitory factor receptor and gp130 cooperate in signal transduction in hepatic and neuronal cells. *Mol. Cell. Biol.* 14: 138–146, 1994.
11. BAUMGARTNER, J. W., C. A. WELLS, C.-M. CHEN, AND M. J. WATERS. The role of the WSXWS equivalent motif in growth hormone receptor function. *J. Biol. Chem.* 269: 29094–29101, 1994.
12. BAZAN, J. F. A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain. *Biochem. Biophys. Res. Commun.* 164: 788–795, 1989.
13. BAZAN, J. F. Haemopoietic receptors and helical cytokines. *Immunol. Today* 11: 350–354, 1990.
14. BERGER, L. C., T. S. HAWLEY, J. A. LUST, S. J. GOLDMAN, AND R. G. HAWLEY. Tyrosine phosphorylation of JAK-TYK kinases in malignant plasma cell lines growth-stimulated by interleukins 6 and 11. *Biochem. Biophys. Res. Commun.* 202: 596–605, 1994.
15. BICHELL, D. P., K. KIKUCHI, AND P. ROTWEIN. Growth hormone rapidly activates insulin-like growth factor I gene transcription in vivo. *Mol. Endocrinol.* 6: 1899–1908, 1992.
16. BILLESTRUP, N., G. ALLEVATO, G. NORSTEDT, A. MØLDRUP, AND J. H. NIELSEN. Identification of intracellular domains in the growth hormone receptor involved in signal transduction. *Proc. Soc. Exp. Biol. Med.* 206: 205–209, 1994.
17. BILLESTRUP, N., P. BOUCHELOUCHE, G. ALLEVATO, M. ILONDO, AND J. H. NIELSEN. Growth hormone receptor C-terminal domains required for growth hormone-induced intracellular free Ca²⁺ oscillations and gene transcription. *Proc. Natl. Acad. Sci. USA* 92: 2725–2729, 1995.
18. BILLESTRUP, N., A. MØLDRUP, P. SERUP, L. S. MATHEWS, G. NORSTEDT, AND J. NIELSEN. Introduction of exogenous growth hormone receptors augments growth hormone-responsive insulin biosynthesis in rat insulinoma cells. *Proc. Natl. Acad. Sci. USA* 87: 7210–7214, 1990.
19. BOUTIN, J.-M., C. JOLICOEUR, H. OKAMURA, J. GAGNON, M. EDERY, M. SHIROTA, D. BANVILLE, I. DUSANTER-FOURT, J. DJIANE, AND P. A. KELLY. Cloning and expression of the rat prolactin receptor, a member of the growth hormone/prolactin receptor gene family. *Cell* 53: 69–77, 1988.
20. BREDT, D. S., AND S. H. SNYDER. Nitric oxide: a physiologic messenger molecule. *Annu. Rev. Biochem.* 63: 175–195, 1994.
21. BURNSIDE, J., S. S. LIOU, AND L. A. COGBURN. Molecular cloning of the chicken growth hormone receptor complementary deoxyribonucleic acid: mutation of the gene in sex-linked dwarf chickens. *Endocrinology* 128: 3183–3192, 1991.
22. CAMERON, C. M., J. L. KOSTYO, N. A. ADAMAFIO, P. BROSTEDT, P. ROOS, A. SKOTTNER, A. FORSMAN, AND L. S. B. FRYKLUND. The acute effects of growth hormone on amino acid transport and protein synthesis are due to its insulin-like action. *Endocrinology* 122: 471–474, 1988.
23. CAMPBELL, G. S., L. J. CHRISTIAN, AND C. CARTER-SU. Evidence for involvement of the growth hormone receptor-associated tyrosine kinase in actions of growth hormone. *J. Biol. Chem.* 268: 7427–7434, 1993.
24. CAMPBELL, G. S., D. J. MEYER, R. RAZ, D. E. LEVY, J. SCHWARTZ,

AND C. CARTER-SU. Activation of acute phase response factor (APRF)/Stat3 transcription factor by growth hormone. J. Biol. Chem. 270: 3974–3979, 1995.

25. CAMPBELL, G. S., T. MIYASAKA, L. PANG, A. R. SALTIEL, AND C. CARTER-SU. Stimulation by growth hormone of MAP kinase activity in 3T3-F442A fibroblasts. J. Biol. Chem. 267: 6074–6080, 1992.

26. CAMPBELL, G. S., E. OGRIS, B. BURKE, W. SU, K. R. AUGER, B. J. DURKER, B. S. SCHAFFHOUSEN, T. M. ROBERTS, AND D. C. PALLAS. Polyoma middle tumor antigen interacts with SHC protein via the NPTY (Asn-Pro-Thr-Tyr) motif in middle tumor antigen. Proc. Natl. Acad. Sci. USA 91: 6344–6348, 1994.

27. CATALIOTO, R. M., G. ALILHAUD, AND R. NEGREL. Diacylglycerol production induced by growth hormone in Ob1771 preadipocytes arises from phosphatidylcholine breakdown. Biochem. Biophys. Res. Commun. 173: 840–848, 1990.

28. CHEATHAM, B., C. J. VLAHOS, L. CHEATHAM, L. WANG, J. BLENIS, AND C. R. KAHN. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol. Cell. Biol. 14: 4902–4911, 1994.

29. CHEEK, D. B., AND D. E. HILL. Effect of growth hormone on cell and somatic growth. In: Handbook of Physiology. Endocrinology. The Pituitary Gland and Its Neuroendocrine Control. Washington, DC: Am. Physiol. Soc., 1974, sect. 7, vol. IV, pt. 2, p. 159–185.

30. CHEN, W. Y., D. C. WIGHT, B. V. MEHTA, T. E. WAGNER, AND J. J. KOPCHICK. Glycine 119 of bovine growth hormone is critical for growth promoting activity. Mol. Endocrinol. 5: 1845–1852, 1991.

31. CHUA, A. O., R. CHIZZONITE, B. B. DESAI, T. P. TRUITT, P. NUNES, L. J. MINETTI, R. R. WARRIOR, D. H. PRESKY, J. F. LEVINE, M. K. GATELY, AND U. GUBLER. Expression cloning of a human IL-12 receptor component. J. Immunol. 153: 128–136, 1994.

32. CIOFFI, J. A., X. WANG, AND J. J. KOPCHICK. Porcine growth hormone receptor cDNA sequence. Nucleic Acids Res. 18: 6451, 1990.

33. CLACKSON, T., AND J. A. WELLS. A hot spot of binding energy in a hormone-receptor interface. Science Wash. DC 267: 383–386, 1995.

34. CLARKSON, R. W. E., C. M. CHEN, S. HARRISON, C. WELLS, G. E. O. MUSCAT, AND M. J. WATERS. Early responses of trans-activating factors to growth hormone in preadipocytes: differential regulation of CCAAT enhancer-binding protein-beta (C/EBPbeta) and C/EBPgamma. Mol. Endocrinol. 9: 108–120, 1995.

35. COBB, M. H., AND E. J. GOLDSMITH. How MAP kinases are regulated. J. Biol. Chem. 270: 14843–14846, 1995.

36. COLOSI, P., K. WONG, S. R. LEONG, AND W. I. WOOD. Mutational analysis of the intracellular domain of the human growth hormone receptor. J. Biol. Chem. 268: 12617–12623, 1993.

37. CORPAS, E., S. M. HARMAN, AND M. R. BLACKMAN. Human growth hormone and human aging. Endocr. Rev. 14: 20–38, 1993.

38. CREWS, C. M., AND R. L. ERIKSON. Extracellular signals and reversible protein phosphorylation: what to MEK of it all. Cell 74: 215–217, 1993.

39. CUNNINGHAM, B. C., M. ULTSCH, A. M. DE VOS, M. G. MULKERRIN, K. R. CLAUSER, AND J. A. WELLS. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science Wash. DC 254: 821–825, 1991.

40. CUNNINGHAM, B. C., AND J. A. WELLS. Comparison of a structural and a functional epitope. J. Mol. Biol. 234: 554–563, 1993.

41. D'ANDREA, A. D., G. D. FASMAN, AND H. F. LODISH. Erythropoietin receptor and interleukin-2 receptor beta chain: a new receptor family. Cell 58: 1023–1024, 1989.

42. DASILVA, L., O. M. Z. HOWARD, H. RUI, R. A. KIRKEN, AND W. L. FARRAR. Growth signaling and JAK2 association mediated by membrane-proximal cytoplasmic regions of prolactin receptors. J. Biol. Chem. 269: 18267–18270, 1994.

43. DAVIDSON, M. B. Effect of growth hormone on carbohydrate and lipid metabolism. Endocrinol. Rev. 8: 115–131, 1987.

44. DAVIS, R. J. The mitogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 268: 14553–14556, 1993.

45. DAVIS, S., T. H. ALDRICH, D. M. VALENZUELA, V. WONG, M. E. FURTH, S. P. SQUINTO, AND G. D. YANCOPOULOS. The receptor for ciliary neurotrophic factor. Science Wash. DC 253: 59–63, 1991.

46. DEKKER, L. V., AND P. J. PARKER. Protein kinase-C: a question of specificity. Trends Biochem. Sci. 19: 73–77, 1994.

47. DEVOS, A. M., M. ULTSCH, AND A. A. KOSSIAKOFF. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science Wash. DC 255: 306–312, 1992.

48. DOGLIO, A., C. DANI, P. GRIMALDI, AND G. AILHAUD. Growth hormone stimulates c-fos gene expression by means of protein kinase C without increasing inositol lipid turnover. Proc. Natl. Acad. Sci. USA 86: 1148–1152, 1989.

49. DRACHMAN, J. G., J. D. GRIFFIN, AND K. KAUSHANSKY. The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. J. Biol. Chem. 270: 4979–4982, 1995.

50. DURIEZ, B., M. L. SOBRIER, P. DUQUESNOY, M. TIXIER-BOICHARD, E. DECUYPERE, G. COQUERELLE, M. ZEMAN, M. GOOSENS, AND S. 'AMSELEM. A naturally occurring growth hormone receptor mutation: in vivo and in vitro evidence for the functional importance of the WS motif common to all members of the cytokine receptor superfamily. Mol. Endocrinol. 7: 806–814, 1993.

51. EILERS, A., D. GEORGELLIS, B. KLOSE, C. SCHINDLER, A. ZIE-MIECKI, A. G. HARPUR, A. F. WILKS, AND T. DECKER. Differentiation-regulated serine phosphorylation of STAT1 promotes GAF activation in macrophages. Mol. Cell. Biol. 15: 3579–3586, 1995.

52. EMTNER, M., L. S. MATHEWS, AND G. NORSTEDT. Growth hormone (GH) stimulates protein synthesis in cells transfected with GH receptor complementary DNA. Mol. Endocrinol. 4: 2014–2020, 1990.

53. FAN, G., AND J. A. RILLEMA. Prolactin stimulation of protein kinase C in isolated mouse mammary gland nuclei. Horm. Metab. Res. 25: 564–568, 1993.

54. FINBLOOM, D. S., E. F. PETRICOIN III, R. H. HACKETT, M. DAVID, G. M. FELDMAN, K.-I. IGARASHI, E. FIBACH, M. J. WEBER, M. O. THORNER, C. M. SILVA, AND A. C. LARNER. Growth hormone and erythropoietin differentially activate DNA-binding proteins by tyrosine phosphorylation. Mol. Cell. Biol. 14: 2113–2118, 1994.

54a. FINBLOOM, D. S., AND K. D. WINESTOCK. IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1α and STAT3 complexes in human T cells and monocytes. J. Immunol. 155: 1079–1090, 1995.

55. FIRMBACH-KRAFT, I., M. BYERS, T. SHOWS, R. DALLA-FAVERA, AND J. J. KROLEWSKI. Tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene 5: 1329–1336, 1990.

56. FOSTER, C. M., J. A. SHAFER, F. W. ROZSA, X. WANG, S. D. LEWIS, D. A. RENKEN, J. E. NATALE, J. SCHWARTZ, AND C. CARTER-SU. Growth hormone promoted tyrosyl phosphorylation of growth hormone receptors in murine 3T3-F442A fibroblasts and adipocytes. Biochemistry 27: 326–334, 1988.

57. FOURCIN, M., S. CHEVALIER, J.-J. LEBRUN, P. KELLY, A. POUPLARD, J. WIJDENES, AND H. GASCAN. Involvement of gp130/interleukin-6 receptor transducing component in interleukin-11 receptor. Eur. J. Immunol. 24: 277–280, 1994.

58. FRANK, S. J., G. GILLILAND, A. S. KRAFT, AND C. S. ARNOLD. Interaction of the growth hormone receptor cytoplasmic domain with the JAK2 tyrosine kinase. Endocrinology 135: 2228–2239, 1994.

59. FRANK, S. J., Y. WOELSUNG, Y. ZHAO, J. F. GOLDSMITH, G. GILLILAND, J. JIANG, I. SAKAI, AND A. S. KRAFT. Regions of the JAK2 tyrosine kinase required for coupling to the growth hormone receptor. J. Biol. Chem. 270: 14776–14785, 1995.

60. FRATTALI, A. L., J. L. TREADWAY, AND J. E. PESSIN. Transmembrane signaling by the human insulin receptor kinase. Relationship between intramolecular beta subunit trans- and cis-autophosphorylation and substrate kinase activation. J. Biol. Chem. 267: 19521–19528, 1992.

61. FRYBURG, D. A., R. A. GELFAND, AND E. J. BARRETT. Growth hormone acutely stimulates forearm muscle protein synthesis in normal humans. Am. J. Physiol. 260 (Endocrinol. Metab. 23): E499–E504, 1991.

62. FU, X.-Y., C. SCHINDLER, T. IMPROTA, R. AEBERSOLD, AND J. E. DARNELL, Jr. The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction. Proc. Natl. Acad. Sci. USA 89: 7840–7843, 1992.

63. FUH, G., B. C. CUNNINGHAM, R. FUKUNAGA, S. NAGATA, D. V. GOEDDEL, AND J. A. WELLS. Rational design of potent antagonists to the human growth hormone receptor. Science Wash. DC 256: 1677–1680, 1992.

October 1996                                                                                               SIGNALING BY GROWTH HORMONE                                                                                              1103

64. FUH, G., M. G. MULKERRIN, S. BASS, N. McFARLAND, M. BROCHIER, J. H. BOURELL, D. R. LIGHT, AND J. A. WELLS. The human growth hormone receptor. Secretion from *Escherichia coli* and disulfide bonding pattern of the extracellular binding domain. *J. Biol. Chem.* 265: 3111–3115, 1990.

65. FUKUNAGA, R., E. ISHIZAKA-IKEDA, AND S. NAGATA. Growth and differentiation signals mediated by different regions in the cytoplasmic domain of granulocyte colony-stimulating factor receptor. *Cell* 74: 1079–1087, 1993.

66. FUKUNAGA, R., E. ISHIZAKA-IKEDA, Y. SETO, AND S. NAGATA. Expression cloning of a receptor for murine granulocyte colony-stimulating factor. *Cell* 61: 341–350, 1990.

67. GAUR, S., H. YAMAGUCHI, AND H. M. GOODMAN. Growth hormone increases Ca²⁺ uptake in rat fat cells by a mechanism dependent on protein kinase C. *Am. J. Physiol.* 270 (Cell Physiol. 39): C1485–C1492, 1996.

68. GAUR, S., H. YAMAGUCHI, AND H. M. GOODMAN. Growth hormone regulates cytosolic free Ca²⁺ in rat fat cells by maintaining L-type calcium channels. *Am. J. Physiol.* 270 (Cell Physiol. 39): C1478–C1484, 1996.

69. GEARING, D. P., M. R. COMEAU, D. J. FRIEND, S. D. GIMPEL, C. J. THUT, J. MCGOURTY, K. K. BRASHER, J. A. KING, S. GILLIS, AND B. MOSLEY. The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. *Science Wash. DC* 255: 1434–1437, 1992.

70. GEARING, D. P., J. A. KING, N. M. GOUGH, AND N. A. NICOLA. Expression cloning of a receptor for human granulocyte-macrophage colony-stimulating factor. *EMBO J.* 8: 3667–3676, 1989.

71. GEARING, D. P., C. J. THUT, T. VANDENBOS, S. D. GIMPEL, P. B. DELANEY, J. KING, V. PRICE, D. COSMAN, AND P. M. BECKMANN. Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130. *EMBO J.* 10: 2839–2848, 1991.

72. GILLE, H., M. KORTENJANN, O. THOMAE, C. MOOMAW, C. SLAUGHTER, M. H. COBB, AND P. E. SHAW. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. *EMBO J.* 14: 951–962, 1995.

73. GILPIN, D. A., R. E. BARROW, R. L. RUTAN, L. BROEMELING, AND D. N. HERNDON. Recombinant human growth hormone accelerates wound healing in children with large cutaneous burns. *Ann. Surg.* 220: 19–24, 1994.

74. GIRI, J. G., M. AHDIEH, J. EISENMAN, K. SHANEBECK, K. GRABSTEIN, S. KUMAKI, A. NAMEN, L. S. PARK, D. COSMAN, AND D. ANDERSON. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. *EMBO J.* 13: 2822–2830, 1994.

75. GODOWSKI, P. J., D. W. LEUNG, L. R. MEACHAM, J. P. GALGANI, R. HELLMISS, R. KERET, P. ROTWEIN, J. S. PARKS, Z. LARON, AND W. I. WOOD. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism. *Proc. Natl. Acad. Sci. USA* 86: 8083–8087, 1989.

76. GOLDSMITH, M. A., W. XU, M. C. AMARAL, E. S. KUCZEK, AND W. C. GREENE. The cytoplasmic domain of the interleukin-2 receptor beta chain contains both unique and functionally redundant signal transduction elements. *J. Biol. Chem.* 269: 14698–14704, 1994.

77. GOMEZ, J., C. PITTON, A. GARCIA, A. MARTINEZ DE ARAGON, A. SILVA, AND A. REBOLLO. The zeta isoform of protein kinase C controls interleukin-2-mediated proliferation in a murine T cell line: evidence for an additional role of protein kinase C epsilon and beta. *Exp. Cell Res.* 218: 105–113, 1995.

78. GONG, T.-W. L., D. MEYER, X. WANG, N. BILLESTRUP, G. NORSTEDT, C. CARTER-SU, AND J. SCHWARTZ. Regulation of c-fos expression and glucose transport by a truncated growth hormone receptor (Abstract). *Proc. Annu. Meet. Endocr. Soc. 76th San Antonio TX* 1994, p. 465.

79. GOODWIN, R. G., D. FRIEND, S. F. ZIEGLER, R. JERZY, B. A. FALK, S. GIMPEL, D. COSMAN, S. K. DOWER, C. J. MARCH, A. E. NAMEN, AND L. S. PARK. Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. *Cell* 60: 941–951, 1990.

80. GORIN, E., AND H. M. GOODMAN. Turnover of growth hormone receptors in rat adipocytes. *Endocrinology* 116: 1796–1805, 1985.

81. GORMAN, D. M., N. ITOH, T. KITAMURA, J. SCHREURS, S. YONEHARA, I. YAHARA, K. ARAI, AND A. MIYAJIMA. Cloning and expression of a gene encoding an interleukin 3 receptor-like protein: identification of another member of the cytokine receptor gene family. *Proc. Natl. Acad. Sci. USA* 87: 5459–5463, 1990.

82. GOUILLEUX, F., C. PALLARD, I. DUSANTER-FOURT, H. WAKAO, L.-A. HALDOSEN, G. HORSTED, D. LEVY, AND B. GRONER. Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity. *EMBO J.* 14: 2005–2013, 1995.

83. GOUJON, L., G. ALLEVATO, G. SIMONIN, L. PAQUEREAU, A. LE CAM, J. CLARK, J. H. NIELSEN, J. DJIANE, M.-C. POSTEL-VINAY, M. EDERY, AND P. A. KELLY. Cytoplasmic sequences of the growth hormone receptor necessary for signal transduction. *Proc. Natl. Acad. Sci. USA* 91: 957–961, 1994.

84. GREENLUND, A. C., M. A. FARRAR, B. VIVIANO, AND R. D. SCHREIBER. Ligand-induced IFN-gamma receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91). *EMBO J.* 13: 1591–1600, 1994.

85. GRONOWSKI, A. M., AND P. ROTWEIN. Rapid changes in nuclear protein tyrosine phosphorylation after growth hormone treatment in vivo. Identification of phosphorylated mitogen-activated protein kinase and Stat91. *J. Biol. Chem.* 269: 7874–7878, 1994.

86. GRONOWSKI, A. M., Z. ZHONG, Z. WEN, M. J. THOMAS, J. E. DARNELL, JR., AND P. ROTWEIN. Nuclear actions of growth hormone: rapid tyrosine phosphorylation and activation of Stat1 and Stat3 after in vivo growth hormone treatment. *Mol. Endocrinol.* 9: 171–177, 1995.

87. GURLAND, G., G. ASHCOM, B. H. COCHRAN, AND J. SCHWARTZ. Rapid events in growth hormone action. Induction of c-fos and c-jun transcription in 3T3-F442A preadipocytes. *Endocrinology* 127: 3187–3195, 1990.

88. HAN, Y., D. W. LEAMAN, D. W. LEAMAN, D. WATLING, N. C. ROGERS, B. GRONER, I. M. KERR, W. I. WOOD, AND G. R. STARK. Participation of JAK and STAT proteins in growth hormone-induced signaling. *J. Biol. Chem.* 271: 5947–5952, 1996.

89. HANSEN, L. H., X. WANG, J. J. KOPCHICK, P. BOUSCHELOUCHE, J. H. NIELSEN, E. D. GALSGAARD, AND N. BILLESTRUP. Identification of tyrosine residues in the intracellular domain of the growth hormone receptor required for transcriptional signaling and Stat5 activation. *J. Biol. Chem.* 271: 12669–12673, 1996.

90. HARDING, P. A., X. Z. WANG, B. KELDER, S. SOUZA, S. OKADA, AND J. J. KOPCHICK. In vitro mutagenesis of growth hormone receptor Asn-linked glycosylation sites. *Mol. Cell. Endocrinol.* 106: 171–180, 1994.

91. HARPUR, A. G., A.-C. ANDRES, A. ZIEMIECKI, R. R. ASTON, AND A. F. WILKS. JAK2, a third member of the JAK family of protein tyrosine kinases. *Oncogene* 7: 1347–1353, 1992.

92. HATAKEYAMA, M., M. TSUDO, S. MINAMOTO, T. KONO, T. DOI, T. MIYATA, M. MIYASAKA, AND T. TANIGUCHI. Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNAs. *Science Wash. DC* 244: 551–556, 1989.

93. HAUSER, S. D., M. F. McGRATH, R. J. COLLIER, AND G. G. KRIVI. Cloning and in vivo expression of bovine growth hormone receptor mRNA. *Mol. Cell. Endocrinol.* 72: 187–200, 1990.

94. HE, T. C., N. JIANG, H. ZHUANG, AND D. M. WOJCOWSKI. Erythropoietin-induced recruitment of Shc via a receptor phosphotyrosine-independent, Jak2-associated pathway. *J. Biol. Chem.* 270: 11055–11061, 1995.

95. HE, T.-C., N. JIANG, H. ZHUANG, D. QUELLE, AND D. M. WOJCOWSKI. The extended box 2 subdomain of erythropoietin receptor is nonessential for Jak2 activation yet critical for efficient mitogenesis in FDC-ER cells. *J. Biol. Chem.* 269: 18291–18294, 1994.

96. HEMMI, S., R. BOHNI, G. STARK, F. DIMARCO, AND M. AGUET. A novel member of the interferon receptor family complements functionality of the murine interferon gamma receptor in human cells. *Cell* 76: 803–810, 1994.

97. HERSHKO, A., AND A. CIECHANOVER. The ubiquitin system for protein degradation. *Annu. Rev. Biochem.* 61: 761–807, 1992.

98. HIBI, M., M. MURAKAMI, M. SAITO, T. HIRANO, T. TAGA, AND T. KISHIMOTO. Molecular cloning and expression of an IL-6 signal transducer, gp130. *Cell* 63: 1149–1157, 1990.

99. HILL, C. S., AND R. TREISMAN. Transcriptional regulation by extracellular signals: mechanisms and specificity. *Cell* 80: 199–211, 1995.

100. HILTON, D. J., A. A. HILTON, A. RAICEVIC, S. RAKAR, M. HARRISON-SMITH, N. M. GOUGH, C. G. BEGLEY, D. METCALF, N. A. NICOLA, AND T. A. WILLSON. Cloning of a murine IL-11 receptor alpha-chain: requirement for gp130 for high affinity binding and signal transduction. *EMBO J.* 13: 4765–4775, 1994.

101. HO, A. S. Y., Y. LIU, T. KHAN, D.-H. HSU, J. F. BAZAN, AND K. W. MOORE. A receptor for interleukin 10 is related to interferon receptors. *Proc. Natl. Acad. Sci. USA* 90: 11267–11271, 1993.

102. HO, J. L., B. ZHU, S. HE, B. DU, AND R. ROTHMAN. Interleukin 4 receptor signaling in human monocytes and U937 cells involves the activation of a phosphatidylcholine-specific phospholipase C: a comparison with chemotactic peptide, FMLP, phospholipase D, and sphingomyelinase. *J. Exp. Med.* 180: 1457–1469, 1994.

103. HUANG, N., L. A. COGBURN, S. K. AGARWAL, H. L. MARKS, AND J. BURNSIDE. Overexpression of a truncated growth hormone receptor in the sex-linked dwarf chicken: evidence for a splice mutation. *Mol. Endocrinol.* 7: 1391–1398, 1993.

104. HUG, H., AND T. F. SARRE. Protein kinase C isoenzymes: divergence in signal transduction? *Biochem. J.* 291: 329–343, 1993.

105. LONDO, M. M., P. DE MEYTS, AND P. BOUCHELOUCHE. Human growth hormone increases cytosolic free calcium in cultured human IM-9 lymphocytes: a novel mechanism of growth hormone transmembrane signalling. *Biochem. Biophys. Res. Commun.* 202: 391–397, 1994.

106. IP, N. Y., S. H. NYE, T. G. BOULTON, S. DAVIS, T. TAGA, Y. LI, S. J. BIRREN, K. YASUKAWA, T. KISHIMOTO, D. J. ANDERSON, N. STAHL, AND G. D. YANCOPoulos. CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 transducing receptor component gp130. *Cell* 69: 1121–1132, 1992.

107. ITOH, N., S. YONEHARA, J. SCHREURS, D. M. GORMAN, K. MARUYAMA, A. ISHII, I. YAHARA, K. ARAI, AND A. MIYAJIMA. Cloning of an interleukin-3 receptor gene: a member of a distinct receptor gene family. *Science Wash. DC* 247: 324–327, 1990.

108. JIANG, Z. M., G. Z. HE, S. Y. ZHANG, X. R. WANG, N. F. YANG, Y. XHU, AND D. W. WILMORE. Low-dose growth hormone and hypocaloric nutrition attenuate the protein-catabolic response after major operation. *Ann. Surg.* 210: 513–524, 1989.

109. JOHNSON, R. M., M. A. NAPIER, M. J. CRONIN, AND K. L. KING. Growth hormone stimulates the formation of sn-1,2-diacylglycerol in rat hepatocytes. *Endocrinology* 127: 2099–2103, 1990.

110. JOHNSTON, J. A., M. KAWAMURA, R. A. KIRKEN, Y.-Q. CHEN, T. B. BLAKE, K. SHIBUYA, J. R. ORTALDO, D. W. McVICAR, AND J. J. O'SHEA. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. *Nature Lond.* 370: 151–153, 1994.

111. KEEGAN, A. D., K. NELMS, M. WHITE, L.-M. WANG, J. H. PIERCE, AND W. E. PAUL. An IL-4 receptor region containing an insulin receptor motif is important for IL-4-mediated IRS-1 phosphorylation and cell growth. *Cell* 76: 811–820, 1994.

112. KELLY, P. A., J. DJIANE, M.-C. POSTEL-VINAY, AND M. EDERY. The prolactin/growth hormone receptor family. *Endocr. Rev.* 12: 235–251, 1991.

113. KISHIMOTO, T., T. TAGA, AND S. AKIRA. Cytokine signal transduction. *Cell* 76: 253–262, 1994.

114. KITAMURA, T., N. SATO, K. ARAI, AND A. MIYAJIMA. Expression cloning of the human IL-3 receptor cDNA reveals a shared beta subunit for the human IL-3 and GM-CSF receptors. *Cell* 66: 1165–1174, 1991.

115. KOTZMANN, H., M. KOLLER, S. CZERNIN, M. CLODI, T. SVOBODA, M. RIEDL, G. BOLTZ-NITULESCU, C. C. ZIELINSKI, AND A. LUGER. Effect of elevated growth hormone concentrations on the phenotype and functions of human lymphocytes and natural killer cells. *Neuroendocrinology* 60: 619–625, 1994.

116. KRENTZ, A. J., F. T. KOSTER, D. M. CRIST, K. FINN, L. Z. JOHNSON, P. J. BOYLE, AND D. S. SCHADE. Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. *J. Acquired Immune Defic. Syndr.* 6: 245–251, 1993.

117. KUHNE, M. R., T. PAWSON, G. E. LIENHARD, AND G.-S. FENG. The insulin receptor substrate 1 associates with the SH2-containing

118. LEBRUN, J.-J., S. ALI, V. GOFFIN, A. ULLRICH, AND P. A. KELLY. A single phosphotyrosine residue of the prolactin receptor is responsible for activation of gene transcription. *Proc. Natl. Acad. Sci. USA* 92: 4031–4035, 1995.

119. LECAM, A., G. PAGES, P. AUBERGER, G. LEcam, P. LEOPOLD, R. BENAROUS, AND N. GLAICHENHAUS. Study of a growth hormone-regulated protein secreted by rat hepatocytes: cDNA cloning, anti-protease activity and regulation of its synthesis by various hormones. *EMBO J.* 6: 1225–1232, 1987.

120. LECHLEIDER, R. J., R. M. FREEMAN, Jr., AND B. G. NEEL. Tyrosyl phosphorylation and growth factor receptor association of the human corkscrew homologue, SH-PTP2. *J. Biol. Chem.* 268: 13434–13438, 1993.

121. LEE, C.-H., W. LI, R. NISHIMURA, M. ZHOU, A. G. BATZER, M. G. MYERS, Jr., M. F. WHITE, J. SCHLESSINGER, AND E. Y. SKOLNIK. Nck associates with the SH2 domain-docking protein IRS-1 in insulin-stimulated cells. *Proc. Natl. Acad. Sci. USA* 90: 11713–11717, 1993.

122. LEUNG, D. W., S. A. SPENCER, G. CACHIANES, R. G. HAMMONDS, C. COLLINS, W. J. HENZEL, R. BARNARD, M. J. WATERS, AND W. I. WOOD. Growth hormone receptor and serum binding protein: purification, cloning and expression. *Nature Lond.* 330: 537–543, 1987.

123. LOBIE, P. E., G. ALLEVATO, J. H. NIELSEN, G. NORSTEDT, AND N. BILLESTRUP. Requirement of tyrosine residues 333 and 338 of the growth hormone (GH) receptor for selected GH stimulated function. *J. Biol. Chem.* 270: 21745–21750, 1995.

124. MARTIAL, J. A., R. A. HALLEWELL, J. D. BAXTER, AND H. M. GOODMAN. Human growth hormone: complementary DNA cloning and expression in bacteria. *Science Wash. DC* 205: 602–607, 1979.

125. MATHEWS, L., B. ENBERG, AND G. NORSTEDT. Regulation of rat growth hormone receptor gene expression. *J. Biol. Chem.* 264: 9905–9910, 1989.

126. MATHEWS, L. S., G. NORSTEDT, AND R. D. PALMITER. Regulation of insulin-like growth factor I gene expression by growth hormone. *Proc. Natl. Acad. Sci. USA* 83: 9343–9347, 1986.

127. MEYER, D. J., G. S. CAMPBELL, B. H. COCHRAN, L. S. ARGET-SINGER, A. C. LARNER, D. S. FINBLOOM, C. CARTER-SU, AND J. SCHWARTZ. Growth hormone induces a DNA binding factor related to the interferon-stimulated 91 kD transcription factor. *J. Biol. Chem.* 269: 4701–4704, 1994.

128. MEYER, D. J., E. W. STEPHENSON, L. JOHNSON, B. H. COCHRAN, AND J. SCHWARTZ. The serum response element can mediate the induction of c-fos by growth hormone. *Proc. Natl. Acad. Sci. USA* 90: 6721–6725, 1993.

129. MIYAZAKI, T., M. MARUYAMA, G. YAMADA, M. HATAKEYAMA, AND T. TANIGUCHI. The integrity of the conserved “WS motif” common to IL-2 and other cytokine receptors is essential for ligand binding and signal transduction. *EMBO J.* 10: 3191–3197, 1991.

130. MODE, A., P. TOLLET, A. STROM, C. LEGRAVEREND, C. LIDDLE, AND J. Å. GUSTAFSSON. Growth hormone regulation of hepatic cytochrome P450 expression in the rat. *Adv. Enzyme Regul.* 32: 255–263, 1992.

131. MØLDRUP, A., N. BILLESTRUP, T. DRYBERG, AND J. H. NIELSEN. Growth hormone action in rat insulinoma cells expressing truncated growth hormone receptors. *J. Biol. Chem.* 266: 17441–17445, 1991.

132. MÖLLER, C., M. EMTNER, P. ARNER, AND G. NORSTEDT. Growth hormone regulation of lipid metabolism in cells transfected with growth hormone receptor cDNA. *Mol. Cell. Endocrinol.* 99: 111–117, 1994.

133. MORGAN, E. T., C. MACGEOCH, AND J. A. GUSTAFSSON. Hormonal and developmental regulation of expression of the hepatic microsomal steroid 16 alpha-hydroxylase cytochrome P-450 apoprotein in the rat. *J. Biol. Chem.* 260: 11895–11898, 1985.

134. MOSLEY, B., M. P. BECKMANN, C. J. MARCH, R. L. IDZERDA, S. D. GIMPEL, T. VANDENBOS, D. FRIEND, A. ALPERT, D. ANDERSON, J. JACKSON, J. M. WIGNALL, C. SMITH, B. GALLIS, J. E. SIMS, D. URDAL, M. B. WIDMER, D. COSMAN, AND L. S. PARK. The murine interleukin-4 receptor: molecular cloning and charac-

terization of secreted and membrane bound forms. *Cell* 59: 335–348, 1989.

135. MÜLLER, M., J. BRISCOE, C. LAXTON, D. GUSCHIN, A. ZIEMIECKI, O. SILVENNOINEN, A. G. HARPUR, G. BARBIERI, B. A. WITTHUHN, C. SCHINDLER, S. PELLEGRINI, A. F. WILKS, J. N. IHLE, G. R. STARK, AND I. M. KERR. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. *Nature Lond.* 366: 129–135, 1993.

136. MURAKAMI, M., M. NARAZAKI, M. HIBI, H. YAWATA, K. YASUKAWA, M. HAMAGUCHI, T. TAGA, AND T. KISHIMOTO. Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. *Proc. Natl. Acad. Sci. USA* 88: 11349–11353, 1991.

137. MYERS, M. G., JR., X. J. SUN, B. CHEATHAM, B. R. JACHNA, E. M. GLASHEEN, J. M. BACKER, AND M. F. WHITE. IRS-1 is a common element in insulin and insulin-like growth factor-1 signaling to the phosphatidylinositol 3′-kinase. *Endocrinology* 132: 1421–1430, 1993.

138. MYERS, M. G., JR., L.-M. WANG, X. J. SUN, Y. ZHANG, L. YENUSH, J. SCHLESSINGER, J. H. PIERCE, AND M. F. WHITE. Role of IRS-1-GRB-2 complexes in insulin signaling. *Mol. Cell. Biol.* 14: 3577–3587, 1994.

139. NEELY, E. K., AND R. G. ROSENFELD. Use and abuse of human growth hormone. *Annu. Rev. Med.* 45: 407–420, 1994.

140. NICHOLSON, S. E., A. C. OATES, A. G. HARPUR, A. ZIEMIECKI, A. F. WILKS, AND J. E. LAYTON. Tyrosine kinase JAK1 is associated with the granulocyte-colony stimulating factor receptor and both become tyrosine-phosphorylated after receptor activation. *Proc. Natl. Acad. Sci. USA* 91: 2985–2988, 1994.

141. NOVICK, D., B. COHEN, AND M. RUBINSTEIN. The human interferon alpha/beta receptor: characterization and molecular cloning. *Cell* 77: 391–400, 1994.

142. OKADA, S., AND J. J. KOPCHICK. Growth hormone stimulates phosphatidylcholine breakdown and activation of protein kinase C in 3T3-F442A cells (Abstract). *Proc. Annu. Meet. Endocr. Soc. 77th Washington DC* 1995, p. 80.

143. O’NEAL, K. D., AND L.-Y. YU-LEE. The proline-rich motif (PRM): a novel feature of the cytokine receptor superfamily. *Lymphokine Cytokine Res.* 12: 309–312, 1993.

144. O’NEILL, T. J., A. CRAPARO, AND T. A. GUSTAFSON. Characterization of an interaction between insulin receptor substrate 1 and the insulin receptor by using the two-hybrid system. *Mol. Cell. Biol.* 14: 6433–6442, 1994.

145. PARINI, P., B. ANGELIN, P. E. LOBIE, G. NORSTEDT, AND M. RUDLING. Growth hormone specifically stimulates the expression of low density lipoprotein receptors in human hepatoma cells. *Endocrinology* 136: 3767–3773, 1995.

146. PATTERSON, P. H., AND H. NAWA. Neuronal differentiation factors/cytokines and synaptic plasticity. *Cell* 72: 123–137, 1993.

147. PATTHY, L. Homology of a domain of the growth hormone/prolactin receptor family with type III modules of fibronectin. *Cell* 61: 13–14, 1990.

148. PAWSON, T., AND J. SCHLESSINGER. SH2 and SH3 domains. *Curr. Biol.* 3: 434–442, 1993.

149. POLOTSKAYA, A., Y. ZHAO, M. B. LILLY, AND A. S. KRAFT. Mapping the intracytoplasmic regions of the alpha granulocyte-macrophage colony-stimulating factor receptor necessary for cell growth regulation. *J. Biol. Chem.* 269: 14607–14613, 1994.

150. QUELLE, D. E., F. W. QUELLE, AND D. M. WOJCOWSKI. Mutations in the WSAWSE and cytosolic domains of the erythropoietin receptor affect signal transduction and ligand binding and internalization. *Mol. Cell. Biol.* 12: 4553–4561, 1992.

151. QUELLE, F. W., N. SATO, B. A. WITTHUHN, R. C. INHORN, M. EDER, A. MIYAJIMA, J. D. GRIFFIN, AND J. N. IHLE. JAK2 associates with the beta chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. *Mol. Cell. Biol.* 14: 4335–4341, 1994.

152. RAO, P., T. KITAMURA, A. MIYAJIMA, AND R. A. MUFSON. Human IL-3 receptor signaling: rapid induction of phosphatidylcholine hydrolysis is independent of protein kinase C but dependent on tyrosine phosphorylation in transfected NIH 3T3 cells. *J. Immunol.* 154: 1664–1674, 1995.

153. RAO, P., AND R. A. MUFSON. Human interleukin-3 stimulates a phosphatidylcholine specific phospholipase C and protein kinase C translocation. *Cancer Res.* 54: 777–783, 1994.

154. RAZ, R., J. E. DURBIN, AND D. E. LEVY. Acute phase response factor, an ISGF3 homologue that integrates diverse signals from cytokines, interferons, and growth factors. *J. Biol. Chem.* 269: 24391–24395, 1994.

155. REN, H. Y., N. KOMATSU, R. SHIMIZU, K. OKADA, AND Y. MIURA. Erythropoietin induces tyrosine phosphorylation and activation of phospholipase C-gamma 1 in a human erythropoietin-dependent cell line. *J. Biol. Chem.* 269: 19633–19638, 1994.

156. RENAULD, J. C., C. DRUEZ, A. KERMOUNI, F. HOUSIAU, C. UYTTHENHOVE, E. VAN ROOST, AND J. VAN SNICK. Expression cloning of the murine and human interleukin 9 receptor cDNAs. *Proc. Natl. Acad. Sci. USA* 89: 5690–5694, 1992.

157. RIDDERSTRÅLE, M., E. DEGERMAN, AND H. TORNQVIST. Growth hormone stimulates the tyrosine phosphorylation of the insulin receptor substrate-1 and its association with phosphatidylinositol 3-kinase in primary adipocytes. *J. Biol. Chem.* 270: 3471–3474, 1995.

158. RIDDERSTRÅLE, M., AND H. TORNQVIST. PI-3-kinase inhibitor wortmannin blocks the insulin-like effects of growth hormone in isolated rat adipocytes. *Biochem. Biophys. Res. Commun.* 203: 306–310, 1994.

159. RIVERA, V. M., C. K. MIRANTI, R. P. MISRA, D. D. GINTY, R.-H. CHEN, J. BLENIS, AND M. E. GREENBERG. A growth factor-induced kinase phosphorylates the serum response factor at a site that regulates its DNA-binding activity. *Mol. Cell. Biol.* 13: 6260–6273, 1993.

160. ROBERTSON, L., T. KERPPOLA, M. VENDRELL, D. LUK, R. SMEYNE, C. BOCCHIARO, J. MORGAN, AND T. CURRAN. Regulation of c-fos expression in transgenic mice requires multiple interdependent transcription control elements. *Neuron* 14: 241–252, 1995.

161. ROGERS, S. A., AND M. R. HAMMERMAN. Growth hormone activates phospholipase C in proximal tubular basolateral membranes from canine kidney. *Proc. Natl. Acad. Sci. USA* 86: 6363–6366, 1989.

162. ROUPAS, P., AND A. C. HERINGTON. Signaling mechanisms involved in the production of diacylglycerol by growth hormone (Abstract). *Proc. Annu. Meet. Endocr. Soc. 77th Washington DC* 1995, p. 346.

163. ROZAKIS-ADCOCK, M., AND P. A. KELLY. Identification of ligand binding determinants of the prolactin receptor. *J. Biol. Chem.* 267: 7428–7433, 1992.

164. RUDLING, M., G. NORSTEDT, H. OLIVECRONA, E. REIHNER, J.-Å. GUSTAFSSON, AND B. ANGELIN. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. *Proc. Natl. Acad. Sci. USA* 89: 6983–6987, 1992.

165. RUDMAN, D., A. G. FELLER, H. S. NAGRAJ, G. A. GERGANS, P. Y. LALITHA, A. F. GOLDBERG, R. A. SCHLENKER, L. COHN, I. W. RUDMAN, AND D. E. MATTSON. Effects of human growth hormone in men over 60 years old. *N. Engl. J. Med.* 323: 1–6, 1990.

166. RUI, H., R. A. KIRKEN, AND W. L. FARRAR. Activation of receptor-associated tyrosine kinase JAK2 by prolactin. *J. Biol. Chem.* 269: 5364–5368, 1994.

167. RUSSELL, S. M., J. A. JOHNSTON, M. NOGUCHI, M. KAWAMURA, C. M. BACON, M. FRIEDMANN, M. BERG, D. W. McVICAR, B. A. WITTHUHN, O. SILVENNOINEN, A. S. GOLDMAN, F. C. SCHMALSTIEG, J. N. IHLE, J. J. OSHEA, AND W. J. LEONARD. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. *Science Wash. DC* 266: 1042–1045, 1994.

168. SALOMON, F., R. C. CUNEO, R. HESP, AND P. H. SONKSEN. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. *N. Engl. J. Med.* 321: 1797–1803, 1989.

169. SANDS, W. A., V. BULUT, A. SEVERN, D. XU, AND F. Y. LIEW. Inhibition of nitric oxide synthesis by interleukin-4 may involve inhibiting the activation of protein kinase C epsilon. *Eur. J. Immunol.* 24: 2345–2350, 1994.

170. SATO, S., T. KATAGIRI, S. TAKAKI, Y. KIKUCHI, Y. HITOSHI, S. YONEHARA, S. TSUKADA, T. KITAMURA, T. WATANABE, AND O. WITTE. IL-5 receptor-mediated tyrosine phosphorylation of SH2/

SH3-containing proteins and activation of Bruton's tyrosine and Janus 2 kinases. J. Exp. Med. 180: 2101–2111, 1994.

171. SCHAMBELAN, M., A. LAMARCA, K. MULLIGAN, C. GRUNFELD, S. KENNEDY, J. BREITMEYER, AND E. DAAR. Growth hormone therapy of AIDS wasting (Abstract). Int. Conf. AIDS 10: 35, 1994.

172. SCHWARTZ, Y., AND H. M. GOODMAN. Refractoriness to the insulin-like effects of growth hormone depends upon calcium. Endocrinology 126: 170–176, 1990.

173. SCHWARTZ, Y., J. L. KOSTYO, AND H. M. GOODMAN. Growth hormone (GH) increases nitric oxide (NO) production in rat adipocytes (Abstract). Proc. Annu. Meet. Endocr. Soc. 77th Washington DC 1995, p. 79.

174. SCHWARTZ, Y., H. YAMAGUCHI, AND H. M. GOODMAN. Growth hormone increases intracellular free calcium in rat adipocytes: correlation with actions on carbohydrate metabolism. Endocrinology 131: 772–778, 1992.

175. SEEBURG, P. H., J. SHINE, J. A. MARTIAL, J. D. BAXTER, AND H. M. GOODMAN. Nucleotide sequence and amplification in bacteria of structural gene for rat growth hormone. Nature Lond. 270: 486–494, 1977.

176. SHIMODA, K., H. IWASAKI, S. OKAMURA, Y. OHNO, A. KUBOTA, F. ARIMA, T. OTSUKA, AND Y. NIHO. G-CSF induces tyrosine phosphorylation of the JAK2 protein in the human myeloid G-CSF responsive and proliferative cells, but not in mature neutrophils. Biochem. Biophys. Res. Commun. 203: 922–928, 1994.

177. SHUAI, K., C. M. HORVATH, L. H. T. HUANG, S. A. QURESHI, D. COWBURN, AND J. E. DARNELL, JR. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 76: 821–828, 1994.

178. SILVA, C. M., R. N. DAY, M. J. WEBER, AND M. O. THORNER. Human growth hormone (GH) receptor is characterized as the 134-kilodalton tyrosine-phosphorylated protein activated by GH treatment in IM-9 cells. Endocrinology 133: 2307–2312, 1993.

179. SILVA, C. M., H. LU, AND R. N. DAY. Characterization and cloning of Stat 5 from IM9 cells and its activation by growth hormone. Mol. Endocrinol. 10: 508–518, 1996.

180. SILVA, C. M., H. LU, M. J. WEBER, AND M. O. THORNER. Differential tyrosine phosphorylation of JAK1, JAK2, and STAT1 by growth hormone and interferon-gamma in IM-9 cells. J. Biol. Chem. 269: 27532–27539, 1994.

181. SILVA, C. M., M. J. WEBER, AND M. O. THORNER. Stimulation of tyrosine phosphorylation in human cells by activation of the growth hormone receptor. Endocrinology 132: 101–108, 1993.

182. SILVENNOINEN, O., C. SCHINDLER, J. SCHLESSINGER, AND D. E. LEVY. Ras-independent growth factor signaling by transcription factor tyrosine phosphorylation. Science Wash. DC 261: 1736–1739, 1993.

183. SILVENNOINEN, O., B. WITTHUHN, F. W. QUELLE, J. L. CLEVELAND, T. YI, AND J. N. IHLE. Structure of the murine JAK2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc. Natl. Acad. Sci. USA 90: 8429–8433, 1993.

184. SKOLNIK, E. Y., C. H. LEE, A. BATZER, L. M. VICENTINI, M. ZHOU, R. DALY, M. G. MYERS, JR., M. BACKER, A. ULLRICH, M. F. WHITE, AND J. SCHLESSINGER. The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling. EMBO J. 12: 1929–1936, 1993.

185. SLOOTWEG, M. C., R. P. DEGROOT, M. P. HERRMANN-ERLEE, I. KOORNNEEF, W. KRULJER, AND Y. M. KRAMER. Growth hormone induces expression of c-jun and jun B oncogenes and employs a protein kinase C signal transduction pathway for the induction of c-fos oncogene expression. J. Mol. Endocrinol. 6: 179–188, 1991.

186. SMAL, J., AND P. DE MEYTS. Role of kinase C in the insulin-like effects of human growth hormone in rat adipocytes. Biochem. Biophys. Res. Commun. 147: 1232–1240, 1987.

187. SMIT, L., AND C. CARTER-SU. Growth hormone receptor. In: Growth Factors and Cytokines in Health and Disease, edited by D. LeRoith and C. Bondy. Greenwich, CT: JAI, 1996, vol. 1A, p. 43–84.

188. SMIT, L. S., D. J. MEYER, N. BILLESTRUP, G. NORSTEDT, J. SCHWARTZ, AND C. CARTER-SU. The role of growth hormone receptor and JAK1 and JAK2 kinases in the activation of Stats 1, 3 and 5 by growth hormone. Mol. Endocrinol. 10: 519–533, 1996.

189. SMITH, W. C., J. KUNIYOSHI, AND F. TALAMANTES. Mouse serum

growth hormone (GH) binding protein has GH receptor extracellular and substituted transmembrane domains. Mol. Endocrinol. 3: 984–990, 1989.

190. SOH, J., R. J. DONNELLY, S. KOTENKO, T. M. MARIANO, J. R. COOK, N. WANG, S. EMANUEL, B. SCHWARTZ, T. MIKI, AND S. PESTKA. Identification and sequence of an accessory factor required for activation of the human interferon gamma receptor. Cell 76: 793–802, 1994.

191. SOTIROPOULOS, A., M. PERROT-APPLANAT, H. DINERSTEIN, A. PALLIER, M.-C. POSTEL-VINAY, J. FINIDORI, AND P. A. KELLY. Distinct cytoplasmic regions of the growth hormone receptor are required for activation of JAK2, mitogen-activated protein kinase, and transcription. Endocrinology 135: 1292–1298, 1994.

192. SOUZA, S. C., G. P. FRICK, R. YIP, R. B. LOBO, L.-R. TAI, AND H. M. GOODMAN. Growth hormone stimulates tyrosine phosphorylation of insulin receptor substrate-1. J. Biol. Chem. 269: 30085–30088, 1994.

193. STAHL, N., T. G. BOULTON, T. FARRUGGELLA, N. Y. IP, S. DAVIS, B. A. WITTHUHN, F. W. QUELLE, O. SILVENNOINEN, G. BARBIERI, S. PELLEGRINI, J. N. IHLE, AND G. D. YANCOPOULOS. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science Wash. DC 263: 92–95, 1994.

194. STAHL, N., T. J. FARRUGGELLA, T. G. BOULTON, Z. ZHONG, J. E. DARNELL, JR., AND G. D. YANCOPOULOS. Modular tyrosine-based motifs in cytokine receptors specify choice of STATs and other substrates. Science Wash. DC 267: 1349–1353, 1995.

195. STUBBART, J. R., D. F. BARTON, P.-K. K. TAI, S. E. STRED, E. GORIN, H. M. GOODMAN, AND C. CARTER-SU. Antibodies to cytoplasmic sequences of cloned liver growth hormone (GH) receptors recognize GH receptors associated with tyrosine kinase activity. Endocrinology 129: 1659–1670, 1991.

196. SUBRAMANIAN, A., J. TEIXEIRA, J. WANG, AND G. GIL. A STAT factor mediates the sexually dimorphic regulation of hepatic cytochrome P450 3A10/lithocholic acid 6β-hydroxylase gene expression by growth hormone. Mol. Cell. Biol. 15: 4672–4682, 1995.

197. SUN, X. J., D. L. CRIMMINS, M. G. MYERS, JR., M. MIRALPEIX, AND M. F. WHITE. Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1. Mol. Cell. Biol. 13: 7418–7428, 1993.

198. SUN, X. J., P. ROTHENBERG, C. R. KAHN, J. M. BACKER, E. ARAKI, P. A. WILDEN, D. A. CAHILL, B. J. GOLDSTEIN, AND M. F. WHITE. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature Lond. 352: 73–77, 1991.

199. SUN, X. J., L.-M. WANG, Y. ZHANG, L. YENUSH, M. G. MYERS, JR., E. GLASHEEN, W. S. LANE, J. H. PIERCE, AND M. F. WHITE. Role of IRS-2 in insulin and cytokine signalling. Nature Lond. 377: 173–177, 1995.

200. TAI, P.-K. K., J.-F. LIAO, E. H. CHEN, J. J. DIETZ, J. SCHWARTZ, AND C. CARTER-SU. Differential regulation of two glucose transporters by chronic growth hormone treatment of cultured 3T3-F442A adipose cells. J. Biol. Chem. 265: 21828–21834, 1990.

201. TAKAKI, S., A. TOMINAGA, Y. HITOSHI, E. SONODA, N. YAMAGUCHI, AND K. TAKATSU. Molecular cloning and expression of the murine interleukin-5 receptor. EMBO J. 9: 4367–4374, 1990.

202. TAKESHITA, T., H. ASAO, K. OHTANI, N. ISHII, S. KUMAKI, N. TANAKA, H. MUNAKATA, M. NAKAMURA, AND K. SUGAMURA. Cloning of the gamma chain of the human IL-2 receptor. Science Wash. DC 257: 379–382, 1992.

203. TANAKA, N., H. ASAO, K. OHBO, N. ISHII, T. TAKESHITA, M. NAKAMURA, H. SASAKI, AND K. SUGAMURA. Physical association of JAK1 and JAK2 tyrosine kinases with the interleukin 2 receptor beta and gamma chains. Proc. Natl. Acad. Sci. USA 91: 7271–7275, 1994.

204. TANNER, J. W., W. CHEN, R. L. YOUNG, G. D. LONGMORE, AND A. S. SHAW. The conserved box 1 motif of cytokine receptors is required for association with JAK kinases. J. Biol. Chem. 270: 6523–6530, 1995.

205. TOKER, A., M. MEYER, K. K. REDDY, J. R. FALCK, R. ANEJA, S. ANEJA, A. PARRA, D. J. BURNS, L. M. BALLAS, AND L. C. CANTLEY. Activation of protein kinase C family members by the novel polyphosphoinositides PtdIns-3,4-P₂ and PtdIns-3,4,5-P₃. J. Biol. Chem. 269: 32358–32367, 1994.

206. TOLLET, P., M. HAMBERG, J.-Å. GUSTAFSSON, AND A. MODE. Growth hormone signaling leading to CYP2C12 gene expression in

rat hepatocytes involves phospholipase A₂. J. Biol. Chem. 270: 12569–12577, 1995.

207. TOLETT, P., C. LEGRVEREND, J.-Å. GUSTAFSSON, AND A. MODE. A role for protein kinases in the growth hormone regulation of cytochrome P4502C12 and insulin-like growth factor-I messenger RNA expression in primary adult rat hepatocytes. Mol. Endocrinol. 5: 1351–1358, 1991.

208. UDDIN, S., L. YENUSH, X. J. SUN, M. E. SWEET, M. F. WHITE, AND L. C. PLANTANIAS. Interferon-alpha engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3′-kinase. J. Biol. Chem. 270: 15938–15941, 1995.

209. UZE, G., G. LUTFALLA, AND I. GRESSER. Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA. Cell 60: 225–234, 1990.

210. VANDERKUUR, J., G. ALLEVATO, N. BILLESTRUP, G. NORSTEDT, AND C. CARTER-SU. Growth hormone-promoted tyrosyl phosphorylation of Shc proteins and Shc association with Grb2. J. Biol. Chem. 270: 7587–7593, 1995.

211. VANDERKUUR, J., X. WANG, L. ZHANG, G. ALLEVATO, N. BILLESTRUP, AND C. CARTER-SU. Growth hormone-dependent phosphorylation of tyrosine 333 and/or 338 of the growth hormone receptor. J. Biol. Chem. 270: 21738–21744, 1995.

212. VANDERKUUR, J. A., X. WANG, L. ZHANG, G. S. CAMPBELL, G. ALLEVATO, N. BILLESTRUP, G. NORSTEDT, AND C. CARTER-SU. Domains of the growth hormone receptor required for association and activation of JAK2 tyrosine kinase. J. Biol. Chem. 269: 21709–21717, 1994.

213. VIGON, I., J.-P. MORNON, L. COCAULT, M.-T. MITJAVILA, P. TAMBOURIN, S. GISSELBRECHT, AND M. SOUYRI. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc. Natl. Acad. Sci. USA 89: 5640–5644, 1992.

214. WAKAO, H., F. GOUILLEUX, AND B. GRONER. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J. 13: 2182–2191, 1994.

215. WANG, L-M., A. D. KEEGAN, W. LI, G. E. LIENHARD, S. PACINI, J. S. GUTKIND, M. G. MYERS, JR., X-J. SUN, M. F. WHITE, S. A. AARONSON, W. E. PAUL, AND J. H. PIERCE. Common elements in interleukin 4 and insulin signaling pathways in factor-dependent hematopoietic cells. Proc. Natl. Acad. Sci. USA 90: 4032–4036, 1993.

216. WANG, L.-M., M. G. MYERS, JR., X.-J. SUN, S. A. AARONSON, M. F. WHITE, AND J. H. PIERCE. IRS-1: essential for insulin- and IL-4-stimulated mitogenesis in hematopoietic cells. Science Wash. DC 261: 1591–1594, 1993.

217. WANG, X., M. UHLER, N. BILLESTRUP, G. NORSTEDT, F. TALAMANTES, J. H. NIELSEN, AND C. CARTER-SU. Evidence for association of the cloned liver growth hormone receptor with a tyrosine kinase. J. Biol. Chem. 267: 17390–17396, 1992.

218. WANG, Y.-D., K. WONG, AND W. I. WOOD. Intracellular tyrosine residues of the human growth hormone receptor are not required for the signaling of proliferation or Jak-STAT activation. J. Biol. Chem. 270: 7021–7024, 1995.

219. WANG, Y.-D., AND W. I. WOOD. Amino acids of the human growth hormone receptor that are required for proliferation and Jak-STAT signaling. Mol. Endocrinol. 9: 303–311, 1995.

220. WATLING, D., D. GUSCHIN, M. MÜLLER, O. SILVENNOINEN, B. A. WITTHUHN, F. W. QUELLE, N. C. ROGERS, C. SCHINDLER, G. R. STARK, J. N. IHLE, AND I. M. KERR. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature Lond. 366: 166–170, 1993.

221. WATOWICH, S. S., A. YOSHIMURA, G. D. LONGMORE, D. J. HILTON, Y. YOSHIMURA, AND H. F. LODISH. Homodimerization and constitutive activation of the erythropoietin receptor. Proc. Natl. Acad. Sci. USA 89: 2140–2144, 1992.

222. WAXMAN, D. J., G. A. LEBLANC, J. J. MORRISSEY, J. STAUNTON, AND D. P. LAPENSON. Adult male-specific and neonatally programmed rat hepatic P-450 forms RLM2 and 2a are not dependent

on pulsatile plasma growth hormone for expression. J. Biol. Chem. 263: 11396–11406, 1988.

223. WAXMAN, D. J., P. A. RAM, S.-H. PARK, AND H. K. CHOI. Intermittent plasma growth hormone triggers tyrosine phosphorylation and nuclear translocation of a liver-expressed, Stat 5-related DNA binding protein. J. Biol. Chem. 270: 13262–13270, 1995.

224. WEGENKA, U. M., C. LUTTICKEN, J. BUSCHMANN, J. YUAN, F. LOTTSPRICH, W. MULLER-ESTERL, C. SCHINDLER, E. ROEB, P. C. HEINRICH, AND F. HORN. The interleukin-6-activated acute-phase response factor is antigenically and functionally related to members of the signal transducer and activator of transcription (STAT) family. Mol. Cell. Biol. 14: 3186–3196, 1994.

225. WELHAM, M. J., L. H. BONE, LEARMONTH, AND J. W. SCHARADER. Interleukin-13 signal transduction in lymphohemopoietic cells. J. Biol. Chem. 270: 12286–12296, 1995.

226. WELLS, J. A., B. C. CUNNINGHAM, G. FUH, H. B. LOWMAN, S. H. BASS, M. G. MULKERRIN, M. ULTSCH, AND A. M. DEVOS. The molecular basis for growth hormone-receptor interactions. Rec. Prog. Horm. Res. 48: 253–275, 1993.

227. WEN, Z., Z. ZHONG, AND J. E. DARNEILL, JR. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82: 241–250, 1995.

228. WILKS, A. F., A. G. HARPUR, R. R. KURBAN, S. J. RALPH, G. ZURCHER, AND A. ZIEMIECKI. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol. Cell. Biol. 11: 2057–2065, 1991.

229. WINSTON, L. A., AND P. J. BERTICS. Growth hormone stimulates the tyrosyl phosphorylation of 42- and 45-kDa ERK-related proteins. J. Biol. Chem. 267: 4747–4751, 1992.

230. WITTHUHN, B. A., F. W. QUELLE, O. SILVENNOINEN, T. YI, B. TANG, O. MIURA, AND J. N. IHLE. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74: 227–236, 1993.

231. WITTHUHN, B. A., O. SILVENNOINEN, O. MIURA, K. S. LAI, C. CWIK, E. T. LIU, AND J. N. IHLE. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature Lond. 370: 153–157, 1994.

232. WOOD, T. J. J., D. SLIVA, P. E. LOBIE, T. PIRCHER, F. GOULLEUX, H. WAKAO, J.-Å. GUSTAFSON, B. GRONER, G. NORSTEDT, AND L.-A. HALDØSEN. Mediation of growth hormone-dependent transcriptional activation of mammary gland factor Stat 5. J. Biol. Chem. 270: 9448–9453, 1995.

233. XU, B. C., X. WANG, C. J. DARIUS, AND J. J. KOPCHICK. Growth hormone promotes the association of transcription factor Stat 5 with the growth hormone receptor. J. Biol. Chem. 271: 19768–19780, 1996.

234. YAMASAKI, K., T. TAGA, Y. HIRATA, H. YAWATA, Y. KAWANISHI, B. SEED, T. TANIGUCHI, T. HIRANO, AND T. KISHIMOTO. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science Wash. DC 241: 825–828, 1988.

235. YIN, T., S. R. KELLERS, F. W. QUELLE, B. A. WITTHUHN, M. L.-S. TSANG, G. E. LIENHARD, J. N. IHLE, AND Y.-C. YANG. Interleukin-9 induces tyrosine phosphorylation of insulin receptor substrate-1 via JAK tyrosine kinases. J. Biol. Chem. 270: 20497–20502, 1995.

236. YIN, T., K. YASUKAWA, T. TAGA, T. KISHIMOTO, AND Y.-C. YANG. Identification of a 130-kilodalton tyrosine-phosphorylated protein induced by interleukin-11 as JAK2 tyrosine kinase, which associates with gp130 signal transducer. Exp. Hematol. 22: 467–472, 1994.

237. YOON, J. B., S. A. BERRY, S. SEELIG, AND H. C. TOWLE. An inducible nuclear factor binds to a growth hormone-regulated gene. J. Biol. Chem. 265: 19947–19954, 1990.

238. ZENG, Y. X., H. TAKAHASHI, M. SHIBATA, AND K. HIROKAWA. JAK3 Janus kinase is involved in interleukin 7 signal pathway. FEBS Lett. 353: 289–293, 1994.

239. ZHONG, Z., Z. WEN, AND J. E. DARNEILL, JR. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science Wash. DC 264: 95–98, 1994.

240. ZURAWSKI, S. M., F. J. VEGA, B. HUYGHE, AND G. ZURAWSKI. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J. 12: 2663–2670, 1993.
